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Modulation of Neural Plasticity by the ADAMTSs (a Disintegrin and 
Metalloproteinase with Thrombospondin Motifs) 
 
Michelle Hamel 
 
ABSTRACT 
 Aggregating proteoglycans (PG) bearing chondroitin sulfate (CS) side 
chains are well-known inhibitors of neural plasticity and associate with 
hyaluronan and tenascin-R to form a complex of extracellular matrix (ECM) in the 
central nervous system (CNS).  Little is known about whether proteolytic 
cleavage of the core protein affects neural plasticity.  Several members of the 
ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family 
of metalloproteinases are glutamyl-endopeptidases that cleave aggregating PGs.  
Our initial studies determined that neural cultures secrete a brevican-containing 
matrix, and that these neural cultures also produced ADAMTS4, a protease that 
cleaves brevican.  Furthermore, this brevican-containing matrix in astrocytes 
could be modulated by treatment with transforming growth factor β (TGFβ) 
through the inhibition of the activity of the ADAMTSs. 
Once it was established that neural cultures produce a brevican-rich 
matrix, we sought to utilize this matrix to determine whether cleavage of 
aggregating PGs, especially brevican, by the ADAMTSs influences neurite 
outgrowth in cultured neurons.  Transfection of rat neurons with ADAMTS4 cDNA 
induced longer neurites, and interestingly, this effect proved to be independent of 
 iv
the proteolytic action of the ADAMTSs.  Addition of recombinant ADAMTS4 or 
ADAMTS5 protein to immature neuronal cultures similarly enhanced neurite 
extension, an action dependent on the activation of extracellular signal-related 
kinase (ERK)1/2 (MAP kinase 42/44), resulting in the first evidence that 
ADAMTSs may induce intracellular signaling events.   
 Studies of dendritic spine morphology and levels of synaptic proteins in 
response to ADAMTS4 treatment were also undertaken.  Neuronal cultures 
treated with ADAMTS4 showed increased length of dendritic spines and 
increased percent of immature spines detected.  A concurrent decrease in post-
synaptic protein staining was detected on the neurites of young neurons 
overexpressing ADAMTS4 or expressing proteolytically-inactive mutant 
ADAMTS4 protein.  Thus, ADAMTS4 may promote plasticity in neurons in vitro 
by preventing the formation, maturation, and/or stabilization of synapses.  
Overall, these experiments provide evidence that implicate the ADAMTSs as 
mediators of neural plasticity, and while primarily known only as proteases, these 
studies demonstrate that the ADAMTSs exert actions distinct from these 
proteolytic properties that require the induction of intracellular signaling events. 
 v
 
 
 
 
 
Introduction 
 
Neural plasticity and proteoglycans 
Neural plasticity is the broad term used to describe the processes that 
occur in the CNS to facilitate the formation of new neural connections.  This is a 
complex process involving proliferation and migration of cells, neuritic sprouting 
and synaptogenesis that occurs between the newly extended processes.  
Plasticity can be defined as functional changes that occur in neurons.  The 
developing brain is highly plastic, whereas plastic changes in mature adult brain 
are more limited but may readily take place in certain regions including 
hippocampus and olfactory bulb.  This is important in terms of injury to the adult 
brain, where a plastic response, if activated, could lead to functional recovery.  
Extensive neurite outgrowth occurs during the development of the CNS, 
and also in response to injury, although to a much greater extent in the peripheral 
nervous system (PNS) compared to the CNS.  Sprouting neurites must traverse 
a circuitous route and penetrate a multifarious extracellular matrix to reach and 
innervate their targets.  Proteoglycans (PG), more specifically those of the 
lectican family, are a major component of this matrix and function in pathfinding, 
cell adhesion and migration.  It is well established that PGs are inhibitors of 
neurite outgrowth.  Lectican expression is extensive in the brain throughout life.  
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Early in development, PGs function in axonal pathfinding as inhibitory guidance 
cues and act as barriers to outgrowing neurites (Snow et al., 1991; Kubota et al., 
1999; Ichijo, 2004; Kantor et al., 2004).  Chondroitin sulfate (CS) chains that are 
covalently linked to the central domain of the PG aid in inhibiting neurite 
outgrowth, and removing these chains allows for increased plasticity (Pizzorusso 
et al., 2002), and in other cases, pathfinding errors (Brittis et al., 1992; Bernhardt 
and Schachner, 2000; Masuda et al., 2004).  In fact, removing the 
glycosaminoglycan (GAG) chains from the PG caused a plastic dominance shift 
in the visual cortex of the adult animal undergoing monocular deprivation 
(Pizzorusso et al., 2002).  Many studies implicate the CS moieties in the ability of 
the PG to inhibit neurite outgrowth since treatment of PGs with the experimental 
enzyme that degrades CS chains, chondroitinase ABC, increases plasticity.  It 
should be noted, however, that chondroitinase ABC degrades hyaluronan, a 
large high molecular weight GAG in the ECM, and thus, this effect may play a 
role in the reactivation of plasticity seen in these experiments.  Other studies 
have shown that the core protein retains a degree of inhibition, although not as 
great at the intact PG, after CS GAG chain removal (Schmalfeldt et al., 2000; 
Ughrin et al., 2003).  Conversely, limited evidence indicates that PGs with little 
GAG chain substitution and those PGs bearing heparan sulfate (HS) chains may 
actually support neurite outgrowth (Hantaz-Ambroise et al., 1987; Kim et al., 
2003).  In vitro studies have shown that upon contacting PGs, growth cones do 
not collapse, but are rather redirected on another path (Snow et al., 2001).  In 
fact, growing neurons in the presence of CS-containing PG results in increased 
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axonal fasciculation (Snow et al., 2003).  Since the core protein does retain the 
ability to attenuate neurite outgrowth, attempts have been made to implicate this 
portion of the molecule in this function as increased neuritic growth is observed 
after core protein cleavage (Zuo et al., 1998).  To date, there is no unifying theory 
as to how PGs inhibit neurite outgrowth, and in fact, several possible 
mechanisms have been proposed to explain the ability of the CS-containing PG 
to attenuate neurite outgrowth so exquisitely.  These proposed mechanisms 
range from receptor mediated processes to sequestering growth factors.  There 
may be an unknown receptor that binds PGs to activate neuritic growth inhibiting 
processes (Carulli et al., 2005).  Another theory is that CSPGs bind growth-
supporting molecules to sequester these factors (Bovolenta and Fernaud-
Espinosa, 2000; Deepa et al., 2002; Carulli et al., 2005), or block the receptors 
for growth factors (Snow and Letourneau, 1992; Smith-Thomas et al., 1994; 
McKeon et al., 1995; Carulli et al., 2005).  Instead of blocking growth promoting 
processes, it may be that PGs aid growth inhibitory processes.  PGs may direct 
inhibitory molecules to their site of action (Emerling and Lander, 1996; Carulli et 
al., 2005) or may even bind receptors that activate cell signals to block neurite 
outgrowth (Carulli et al., 2005).  There are many possible mechanisms but no 
convincing data to this date to determine the mechanism of action of the PG in 
inhibiting neurite outgrowth. 
While PGs are important in pathfinding and development, they are also 
highly expressed in the glial scar, the accumulation of reactive astrocytes and 
deposition of ECM components that occurs in response to injury to restrict the 
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growth of axons into a damaged area of the CNS.  The CNS responds to injury 
by recruiting cell types like microglia and oligodendrocyte precursors to the injury 
site.  These cells work in concert with reactive astrocytes to express several 
growth-restricting molecules, one of the most highly expressed being lecticans 
(Tang et al., 2003).  Several other inhibitory components are expressed as well, 
like the glycoprotein tenascin and the myelin-associated inhibitor Nogo-A (Asher 
et al., 2001).  The application of chondroitinase ABC to degrade the CS chains of 
PGs expressed in response to injury such as nigrostriatal tract axotomy or spinal 
cord lesion results in increased axonal regeneration (Moon et al., 2001; Bradbury 
et al., 2002).  Therefore, due to their expression pattern and well known role in 
restricting neuritic growth, the modulation of PGs is promising as a means to 
activate plasticity in the adult CNS. 
When attempting to enhance plasticity in the CNS, neurite outgrowth is 
important, but insignificant if these new axons do not form functional connections.  
Currently, interest is increasing as to how ECM components influence changes in 
the morphology of synapses, rather than changes in the conductance of the 
neuron.  Dendritic spines, the site for excitatory neurotransmission in the CNS, 
are a very common method to measure alterations in synaptic morphology since 
these protrusions show some degree of morphological plasticity in adult CNS.  
An array of various proteins is important in regulating the formation and alteration 
of dendritic spines, which are highly enriched in actin and thus highly motile 
structures.  Lecticans surround dendritic spines except at the synapse, however, 
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their function in synaptic modulation has been speculated to be important, and is 
supported by indirect evidence.   
Lecticans and perineuronal nets 
Perineuronal nets (PNN), which ensheathe certain neurons to form an 
isolated microenvironment, are thought to be important in the regulation of 
synaptic plasticity.  Neurons and glia secrete the components of the PNN (Celio 
and Blumcke, 1994).  In the brain, ECM localizes to the intracellular spaces 
between neurons and glia and also coats the neuronal surface, and is deposited 
in neuropil and white matter.  The four proteoglycans of the lectican family, 
aggrecan, neurocan, versican and brevican share significant homology and are 
the chief components in brain ECM of neuropil and PNNs.  The four lecticans 
share homologous structural motifs, namely the G1 globular domain located at 
the N-terminus, and the G3 globular domain located at the C-terminus.  There is 
also a non-homologous central domain that contains varying numbers of 
attachment sites for CS chains.  The lecticans differ mainly in their lengths, 
degree of CS attachment and expression pattern in the brain.  The G1 domain 
contains binding motifs for hyaluronan and the G3 domain binds tenascin, both of 
which are found in PNNs (Yamaguchi, 2000).  Several studies have 
demonstrated binding as well as co-localization of the lecticans with hyaluronan 
and tenascin, and hyaluronan and tenascin are part of PNNs (Aspberg et al., 
1997; Hagihara et al., 1999).  Thus, it is thought that the binding of these three 
components form the contents of the PNN.  The tightness of the lattice can be 
altered by substituting lecticans of differing lengths or by proteolytic cleavage of 
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the lectican (Yamaguchi, 2000).  Indeed, lectican protein fragments of similar 
size are detected in many tissues, including the brain, suggesting that there is a 
conserved sequence at which extracellular proteolytic cleavage occurs. 
 Lecticans are detected as components of PNNs and in region-specific 
staining patterns in the neuropil (Bignami et al., 1993; Bertolotto et al., 1996).  
PNNs typically envelope GABAergic interneurons, although PNNs are not limited 
to these neurons.  Staining of lecticans on PNNs and in the neuropil correlate 
with staining of hyaluronan and tenascin in the mouse hippocampus, lending 
further credence to the idea that these components interact to form a lattice in 
the ECM (Bruckner et al., 2003).   
Evidence indicates that the lectican/tenascin/hyaluronan complex does 
have functional relevance in the brain.  Mice deficient in tenascin-R expression 
results in abnormal distribution of ECM components, including brevican, although 
there is no structural change in the synapse.  There is altered long term 
potentiation (LTP) in tenascin-R deficient mice, and this is similar to changes that 
occur in a brevican knock-out mouse (Saghatelyan et al., 2001; Brakebusch et 
al., 2002).  The C-terminal G3 domain of the lecticans contain attachment sites 
for carbohydrate moieties like tenascin and sulfoglucuronyl glycolipids.  This 
binding with non GAG chain-containing brevican promotes neuronal adhesion 
and neurite outgrowth (Miura et al., 2001), and  hyaluronan associated adhesive 
cues influence positioning of entorhinal fibers in the hippocampus (Forster et al., 
2001).  Thus, PGs and ECM cues may be important in neural plasticity in the 
adult brain. 
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The lecticans brevican, versican V2 and aggrecan are expressed after the 
dendritic pruning critical period and levels remain high in the adult when 
synapses are cemented.  Additionally, lecticans are deposited around synapses, 
and these facts taken together offer evidence that lecticans may be important in 
synaptic stabilization.  Lectican expression is developmentally regulated with 
neurocan and versican V1 being expressed at high levels in the young animal, 
while brevican, versican V2 and aggrecan are expressed beginning at postnatal 
day 10 in the rat with levels peaking at postnatal day 100.  These high levels 
persist throughout life (Milev et al., 1998).  Brevican in particular is highly 
expressed in the neuropil of adult brain and localizes perisynaptically, leading to 
the hypothesis that brevican is important in the stabilization of synapses 
(Hockfield et al., 1990; Koppe et al., 1997; Yamaguchi, 2000; Mayer et al., 2005).  
The presence of brevican is thought to render a synapse more static and 
resistant to plasticity, and may even inhibit the formation of new synapses.  
Brevican is a unique member of the lectican family of PGs, and exists as a “part-
time” proteoglycan, and in fact, about 50% of the brevican in the brain exists 
without any CS or other sugars (Yamada et al., 1994).  Additionally, brevican is 
alternatively spliced to produce a GPI signal sequence that results in the protein 
covalently tethered to the membrane (Seidenbecher et al., 1995), although the 
cell type producing GPI brevican remains unclear (Seidenbecher et al., 1998; 
Jaworski et al., 1999).  The GPI and secreted forms of brevican are concentrated 
in synaptic fractions and associate with lipid rafts (Seidenbecher et al., 2002).  
Interestingly, brevican knock-out mice show no obvious deficits in behavior or 
 7
learning, but have a phenotype of impaired LTP.  It has not been examined, 
however, whether a compensatory increase in other lectican family members 
resulted from deficiencies in brevican and may explain why these mice have little 
neurological phenotype.  Similarly, LTP can be impaired by infusing anti-brevican 
antibodies into the brains of wild-type mice (Brakebusch et al., 2002).  At any 
rate, impaired LTP certainly demonstrates that brevican is important for the 
formation of new memories at the molecular level.  A quadruple knockout mouse 
was created recently lacking expression of brevican, neurocan, tenascin-R and 
tenascin-C.  The only abnormality displayed by this mouse is increased fibulin 
expression that assumedly is compensating for the loss of tenascin (Rauch et al., 
2005), but further characterization of these animals is necessary to fully 
understand the phenotype. 
Other PG families demonstrate a role in synaptogenesis, suggesting that 
molecules similar to PGs with CS side chains may also modulate synapse 
formation.  Enzymatically degrading the HS chains in neuronal cultures disrupts 
the action of neural cell adhesion molecule (NCAM) to activate synaptogenesis 
(Dityatev et al., 2004).  Overexpressing the HSPG syndecan-2 induces mature 
dendritic spine formation in immature neuronal cultures presumably by 
interacting with Eph receptors (Ethell and Yamaguchi, 1999).  In the PNS, agrin, 
a HSPG, is essential for proper development and function of the neuromuscular 
junction (Werle and VanSaun, 2003).  Since the mechanism of HS in synaptic 
function is unclear, it is difficult to speculate whether CSPGs could act in a similar 
fashion, although it is reasonable to believe that they may. 
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Degradation of extracellular matrix 
In addition to a role for GAG side chains, perhaps modulating the 
inhibitory ECM by cleavage of the PG core protein through endogenous 
proteases could lead to altered synaptic plasticity.  Proteolytic cleavage and 
degradation of ECM occurs through proteases of three major families: the matrix 
metalloproteinases (MMP), the plasminogen activator-plasmin system and the 
ADAMTSs.  The MMPs are Ca++ and Zn++ dependent proteases that cleave ECM 
and are latent pro-proteases.  As degradation of the matrix needs to be tightly 
controlled, their regulation occurs through several mechanisms.  There are 
controls in gene expression, activation of the pro-protease and inhibition of the 
protease with the tissue inhibitors of metalloproteinases (TIMP).  Furthermore, 
MMPs, as well as ADAMTSs and ADAMs are maintained in their inactive state by 
a Zn++ non-covalently bound to an unpaired cysteine residue, known as a 
“cysteine switch” in the pro-domain of the protease.  In vitro, autocatalysis occurs 
when the Zn++-cysteine interaction is disturbed by free radicals, organomercurial 
compounds or proteolysis, resulting in an activated protease.  Many studies have 
revealed changes in MMP expression in CNS injury and pathology models (Yong 
et al., 2001), and mounting evidence indicates both a detrimental and beneficial 
role for the MMPs.   
 The ADAMTSs are the most recently cloned family of ECM-degrading 
proteases.  They are similar in structure to the ADAM family of proteases and cell 
surface adhesion proteins.  The ADAMTSs cleave PGs, including aggrecan 
(Tortorella et al., 1999), brevican (Matthews et al., 2000); and versican V2 
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(Westling et al., 2004).  Currently, there are 19 members described that belong to 
this family of proteins with widespread expression, and several members are 
expressed and proteolytically active in brain.  Certain ADAMTSs are secreted as 
latent pro-proteases and activated by cleavage at a furin-like site in the pro-
domain of the molecule.  ADAMTSs are secreted and anchor to the cell surface 
or ECM by their C-terminal spacer domain or thrombospondin (TSP) repeats, 
which bind GAG chains on HS or glycolipids (Nagase and Kashiwagi, 2003).  
The TSP motifs, along with the spacer region, mediate lectican (and presumably 
other substrates) binding to protease (Kashiwagi et al., 2004, Fig. 1).   
 
Figure. 1: Protein Domains of ADAMTS4.  ADAMTS family members contain 
several conserved protein domains important in protease functionality.  These 
domains include an N-terminal pro-domain that is cleaved by a furin-like protease 
upon secretion to aid in activation of the enzyme, a catalytic domain that is 
responsible for proteolytic capacity, a disintegrin domain that is similar to snake 
venom reprolysins (Dis), a Thrombospondin type I motif (Tsp), cysteine rich 
region (Cys) and a C-terminal spacer domain that is successively cleaved to 
reveal lower molecular weight isoforms of ADAMTS4. 
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Figure. 1: Protein Domains of ADAMTS4. 
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ADAMTSs cleave aggrecan, versican and brevican at a conserved 
sequence located near the N-terminus of the GAG chain containing central 
domain (Yamaguchi, 2000).  Interestingly, this is the only portion of the central 
domain where the lecticans share a high degree of homology.  ADAMTS4 and 
ADAMTS1 mRNA are induced in rat brain after kainic acid injection (Yuan et al., 
2002).  Little is known about ADAMTS expression in CNS pathology states or if 
cleavage of the PG results in altered biological function of the PG.  Our 
laboratory demonstrated that ECL increases ADAMTS4 expression with a 
concomitant increase in the ADAMTS cleaved fragment of brevican (Yuan et al., 
2002; Mayer et al., 2005).  Recent findings also indicate that versican’s G3 
proteolytically derived fragment increases neurite outgrowth and results in the 
activation of extracellular signal-related kinase (ERK) 1/2 (Xiang et al., 2006), 
lending credence to the belief that the ADAMTSs indeed have important 
physiological function.  Additionally, treating rat astrocytes with ß amyloid 
increases the ADAMTS4 transcript (Satoh et al., 2000).  TIMPs are endogenous 
inhibitors of MMPs and the ADAMTSs (Nagase and Brew, 2003) and TIMP 
expression in the brain is increased in response to injury.  TIMP-1 has been 
implicated as an immediate early gene in response to the excitotoxin, kainate 
(Jaworski, 2000).  TIMP-3 potently inhibits the action of ADAMTS4 (Kashiwagi et 
al., 2001). 
 In in vitro situations, ADAMTSs are nearly always found associated with 
cell membranes, and this suggests that members of this family bind cell proteins 
or extracellular matrix proteins that are in close association with the cell surface, 
and it is largely unknown whether these proteins are transmembrane, GPI-linked 
or localized near the cell surface.  The TSP repeats aid in ADAMTS binding to 
HS (Kuno and Matsushima, 1998), and in fact, the HSPG syndecan-1 was 
recently shown to bind the shortest C-terminally processed fragment of 
ADAMTS4 in chondrosarcoma cells.  Sulfated GAG chains affect this binding, 
and in fact, both HS and CS of syndecan were required for ADAMTS4 to bind 
(Gao et al., 2004).  Syndecan-1 may direct ADAMTS4 to its receptor at the cell 
surface or ADAMTS4 may modulate syndecan-1 signaling itself.  Another 
member of the syndecan family, syndecan-2, is highly expressed by mature 
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dentate granule neurons and neurons from other brain regions at post-synaptic 
sites where it is linked to CASK/LIN-2 scaffolding proteins also involved in 
signaling (Hsueh and Sheng, 1999).  Syndecan signaling induces maturation of 
dendritic spines (Ethell and Yamaguchi, 1999; Ethell et al., 2001).  Thus, 
modulation of syndecan signaling by ADAMTS4 could potentially alter synaptic 
function and plasticity.   
 Recent advances have shown the involvement of ECM proteases in 
pathological processes in the nervous system.  Although most of this research is 
descriptive, showing changes in levels or localization of mRNA and/or protein, 
this early progress is encouraging further probing into the effects of ECM-
degrading proteases in disease processes since these studies show time 
dependent changes in these proteases in response to injury.  While these early 
studies are necessary to lay the foundation for the edifice of discovery, further 
studies are necessary to reveal the action of these proteases in injury and 
plasticity since the expression of the protease is often coupled with the 
expression of its inhibitor, the TIMPs, and thus simply noting the expression of an 
ADAMTS does not necessarily mean it is proteolytically active.  Disease models 
yield clues that ADAMTSs are physiologically relevant, and the studies presented 
here seek to determine whether brevican cleavage by ADAMTSs can modulate 
neurite outgrowth and synaptogenesis in vitro.   
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Chapter 1: Altered Production and Proteolytic Processing of Brevican by 
Transforming Growth Factor ß in Cultured Astrocytes 
 
Abstract 
Brevican, a proteoglycan of the lectican family, inhibits neurite outgrowth 
and may also stabilize synapses.  Little is known about its expression or function 
in vitro.  This study seeks to determine whether a brevican-containing matrix is 
present in neural cultures, and if so, how the production of brevican may be 
modulated.  To accomplish this, the content of brevican and its proteolytic 
fragments were measured in primary cultures of neurons, astrocytes and 
microglia after treatment with cytokines.  These experiments revealed that 
astrocytes and neurons express several isoforms of brevican, whereas microglia 
do not produce this proteoglycan.  Cleavage fragments of brevican were found 
primarily in neuronal and astrocyte culture medium.  ADAMTS4 (a disintegrin and 
metalloproteinase with thrombospondin motifs), a protease that selectively 
cleaves lecticans, was detected in cultures of neurons, astrocytes and microglia.  
When astrocytes were challenged with various cytokines, it was found that 
treatment with transforming growth factor β (TGFβ) resulted in a marked increase 
in intact brevican in the culture medium that was accompanied by a trend for a 
decrease in ADAMTS-generated fragments of brevican and apparent ADAMTS 
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activity.  Thus, TGFβ may play a role in neuronal plasticity through its regulation 
of brevican and the activity of the ADAMTSs. 
 
Introduction 
 In the nervous system, extracellular matrix (ECM) exists in the neuropil 
and in discrete reticular networks around the surface of neurons, termed 
perineuronal nets.  The matrix is thought to exist as a complex of aggregated 
molecules whose components include hyaluronan, tenascin-R and one or more 
members of the lectican family of proteoglycans (PGs).  Each of the PGs in the 
lectican family, brevican, versican, aggrecan and neurocan, are variably 
substituted with chondroitin sulfate (CS) chains in the central domain of the core 
protein, and the globular N-terminus binds hyaluronan whereas the C-terminus 
binds tenascin-R (Yamaguchi 2000).  Among the lecticans, brevican is the most 
abundant PG in the ECM of the central nervous system (CNS), and is secreted 
by astrocytes and neurons (Seidenbecher et al. 1998; Jaworski et al. 1999) 
where it is located perisynaptically (Hagihara et al. 1999) in association with 
synaptic proteins (Seidenbecher et al. 2002).  This aggregated complex of matrix 
is thought to confer stability in neural networks and inhibit plasticity after injury 
(Rhodes and Fawcett 2004).  Interestingly, treatment of the tissue with 
chondroitinase markedly improves plasticity, including neurite outgrowth, after 
injury in vivo (Moon et al. 2001).   
In adult CNS, secreted brevican is found as a CS-substituted, high 
molecular weight isoform (Fig. 2A), a 145 kD unsubstituted core protein (Fig. 2B), 
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and as 55 (Fig. 2C) and 80 kD (Fig. 2D, 2E) N- and C-terminal fragments as a 
result of proteolytic cleavage (Yamada et al. 1994).  The major family of 
proteases responsible for the generation of these lower molecular weight 
fragments is the ADAMTS (a disintegrin and metalloproteinase with 
thrombospondin motifs) family, (Tortorella et al. 1999; Matthews et al. 2000), 
although the matrix metalloproteinases (MMPs) are also able to cleave lecticans 
(Nakamura et al., 2000).  The cleavage of brevican and other lecticans by the 
ADAMTSs may result in a loosening of the lectican-hyaluronan-tenascin matrix, 
thus providing conditions more suitable for neuronal plasticity, yet little evidence 
supports such a notion (Yuan et al. 2002).   
 
Figure 2. Schematic demonstrating isoforms, cleavage products, and antibody 
recognition sites of brevican. 
 
 16
Figure 2. Schematic demonstrating isoforms, cleavage products, and antibody 
recognition sites of brevican.  Brevican exists as a >145 kD proteoglycan that 
contains variable numbers (1-3) of CS chains attached to the core protein (A); a 
145 kD core protein devoid of CS chains (B); a 55 kD N-terminal fragment 
derived from ADAMTS cleavage that generates the C-terminal neoepitope 
sequence EAVESE (C); a > 80 kD fragment containing CS chains (D) or an 80 
kD C-terminal fragment (E) that are the proteolytic cohorts to the 55 kD fragment.  
Proteolytic cleavage of brevican is not limited to the ADAMTSs and likely 
includes cleavage by the MMPs which also generates a ~55 kD product.  The 
anti-EAVESE antibody recognizes the neoepitope sequence generated by 
ADAMTS cleavage at the C-terminus of the 55 kD fragment (C).  The anti-
brevican antibody recognizes a sequence in the N-terminal globular domain of 
brevican and recognizes the forms illustrated in (A), (B) and (C). 
 
Although there is substantial data about brevican and its expression and 
localization in the CNS (Bruckner et al., 2003), little is known about the 
production of brevican in vitro, and nothing is known of its association with an in 
vitro matrix.  Brevican mRNA transcript was detected in cultures of cerebellar 
astrocytes, but not in neurons derived from cerebral cortex (Yamada et al. 1994).  
Other efforts have been made to mimic an in vivo matrix by adding exogenous 
components of the matrix aggregate to cell cultures, especially astrocyte cultures 
(Deyst and Toole 1995; Maleski and Hockfield 1997).  The related proteoglycan, 
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neurocan, was found in conditioned medium and as a pericellular, substrate 
bound ECM protein in astrocytes in culture (Asher et al., 2000).   
 We were interested in whether brevican is produced by primary astrocytes 
in culture, whether it is associated with any complex matrix present in the 
cultures and whether factors such as cytokines may regulate brevican production 
in astrocytes in vitro.  Considerable evidence indicates that the cytokine, 
transforming growth factor (TGF)β is an important regulator of multiple matrix 
components including tenascin, fibronectin, collagen, thrombospondin and 
especially PGs (Taipale et al. 1998).  In culture systems from a variety of tissues 
including lung fibroblasts (Venkatesan et al. 2002), prostatic stromal cells (Sakko 
et al. 2001), bovine tendon tissue explants (Robbins et al. 1997), human 
fibroblasts (Kahari et al. 1991), and articular chondrocytes (Morales and Roberts 
1988; Morales et al. 1991), TGFβ markedly stimulated the production of PGs.  In 
addition, when endogenous TGFβ activity was inhibited by RNA interference 
(RNAi) or antibody, there was a significant decline in PG production or the 
development of a pericellular matrix (Deyst and Toole 1995; Merrilees et al. 
2000).  The aim of the present study was to characterize the secretion of 
brevican isoforms by cells of the nervous system, especially astrocytes, and to 
identify factors that regulate the secretion of brevican in astrocytes.   
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Materials and Methods 
Animals and Materials 
 All animal protocols used in this study were approved by the Institutional 
Animal Care and Use Committee at the University of South Florida.  Timed 
pregnant Sprague-Dawley rats were obtained from Harlan (Indianapolis, IN), 
Taconic (Germantown, NY) or Charles River Laboratories (Wilmington, MA).  
Human recombinant TGFβ1, human recombinant interleukin-(IL)-1β and human 
recombinant vascular endothelial growth factor (VEGF) were obtained from 
PeproTech (Rocky Hill, NJ).  Tissue culture media, animal sera, trypsin and 
antibiotic/antimycotic solution were purchased from Mediatech (Herndon, VA) or 
Gibco Invitrogen (Carlsbad, CA).  Cell culture plasticware used in these 
experiments was from Costar (Acton, MA.) or Sarstedt (Nümbrecht, Germany), 
supplies for electrophoresis were obtained from Invitrogen (Carlsbad, CA) and all 
other general chemicals were obtained from Sigma-Aldrich (St. Louis, MO). 
 
Enriched Cultures of Rat Astrocytes, Neurons and Microglia 
 For mixed glial cultures, one to three day-old Sprague-Dawley rat pups 
were euthanized and whole brains removed from the skull.  The meninges and 
cerebellum were removed in sterile isotonic buffer (137mM NaCl, 5.4mM KCl, 
0.17mM Na2HPO4, 0.22mM KH2PO4, 5.5mM glucose, 59mM sucrose), chopped 
into 1mm cubes, and the tissue incubated in 0.25% trypsin, 0.05% EDTA at 37° 
for 12 minutes, vortexing every 4 minutes.  The disrupted tissue was then 
triturated, the cells centrifuged and recovered, and 1x107 cells plated on poly-l-
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lysine-pre-coated (Sigma-Aldrich, St. Louis, MO) 100mm dishes in 10ml of 
Dulbecco’s Modified Eagle’s medium (DMEM) containing 10% horse serum, 
2.5% fetal bovine serum and 1% antibiotic-antimycotic solution.  Medium was 
changed after four days of culture, and after 7 days for astrocyte cultures, the 
dishes containing confluent mixed glia were shaken to remove microglia, the 
supernatant recovered for culture of microglia, and the enriched astrocytes were 
disrupted with trypsin, and 2 x 105 cells were plated onto poly-l-lysine-pre-coated 
24-well tissue culture dishes.  Astrocytes were grown for an additional 7 days at 
which time the cultures were confluent and underwent treatment.  Microglia were 
isolated by differential adherence to plastic as described (Gottschall et al. 1995).  
On the day of the experiment for astrocytes and microglia, cells were washed 
twice with Hank’s balanced salt solution, and treatments were added to the cells 
in 0.5ml of serum-free Opti-Mem medium containing 1% antibiotic-antimycotic 
solution and the cells incubated for 72 h.  At this time, the morphology of the 
astrocytes appeared as a cobblestone-like monolayer with fibrous, process-
bearing phase dark cells scattered on top.  More than 99% of these cells were 
immunoreactive with anti-glial fibrillary acidic protein (Gottschall and Yu 1995).  
At the end of 72 h, medium was collected and astrocytes or microglia were lysed 
with cold extraction buffer (20mM Tris-HCl, 5mM EDTA, 1% Triton X-100, 
pH=7.4, with protease inhibitor cocktail, set III (Calbiochem, La Jolla, CA) added 
at a dilution of 1:100) on ice.  The medium and cell lysates were stored at -80°C 
until analysis by Western blot.   
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 Neurons were derived from embryonic day 18 cerebral cortices, cultured 
and plated as described except that the cultures (2.5 x 105 cells in 12-well culture 
well) were incubated in serum-containing DMEM overnight after plating and the 
next day the medium was changed to Neurobasal containing B27 supplement, 
0.5 mM Glutamax-I (Invitrogen, Carlsbad, CA)  and 0.25 µM glutamate.  The 
medium was not changed for 14 days, and at the end of this time, the medium 
and lysate was collected as described above for astrocytes.   
 
Generation of anti-Peptide Antibodies 
Two antibodies used in this study were custom generated by Sigma-
Genosys (The Woodlands, TX).  Amino acid sequences were chosen and 
submitted to Sigma-Genosys for peptide synthesis.  The peptide was coupled to 
keyhole limpet hemocyanin (KLH), and rabbits were inoculated with the 
conjugate.  Rabbit serum was collected by Sigma-Genosys and the antibody was 
affinity purified using solid phase support coupled to the peptide in our laboratory.  
The eluate from the column was dialyzed overnight, and the purified antibody 
was characterized with Western blot and peptide blocking experiments to ensure 
specificity.  The anti-EAVESE antibody was generated with the peptide 
CGGGQEAVESE, which corresponds to the neoepitope, C-terminus of the N-
terminal brevican fragment (rat) generated by cleavage with ADAMTS at 395Glu -
Ser396 (Matthews et al. 2000).  The anti-ADAMTS4 antibody was generated with 
the peptide CAPLHLPVTFPGKDYDADRQ, which corresponds to a sequence in 
the disintegrin-like domain of rat (and mouse) ADAMTS4. 
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Immunoblotting 
 Culture medium and cell lysates were subjected to SDS-PAGE, followed 
by electrophoretic transfer onto "Immobilon" polyvinylidene fluoride (PVDF) 
membranes (Millipore, Billerica, MA) using standard conditions.  Before adding 
cell lysates to the gel, protein concentration was measured and equal amounts of 
protein were applied to the gel: 14µg for the anti-brevican and anti-EAVESE gels 
and 22µg for the anti-ADAMTS4 gels.  In the conditioned medium, the presence 
of interfering substances prevented protein measurement, and thus equal 
volumes of unconcentrated medium underwent SDS-PAGE and subsequent 
blotting for the medium lanes of the characterization experiments and the TGFß 
treatments.  To ensure equal protein loading for the experiments where medium 
was used, the membranes were stained with Coomassie blue, and the bands 
visualized to confirm equal density of color.  The membranes were probed with 
several antibodies against ECM proteins and ADAMTS4.  Mouse anti-brevican 
(BD Biosciences, San Jose, CA) was used at a dilution of 1:1000, rabbit anti-
ADAMTS4 antibody at 1:1000 and rabbit anti-EAVESE antibody at a dilution of 
1:100.  Horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG and 
HRP-conjugated goat anti-rabbit IgG secondary antibodies (Chemicon, 
Temecula, CA) were used at a dilution of 1:1000.  Blots were developed with 
"SuperSignal" West Pico Chemiluminescent substrate (Pierce, Rockford, IL), and 
chemiluminescent signal was detected on photographic film (Pierce, Rockford, 
IL). 
 
 22
Data Analysis 
 Optical density (OD) of specific signals on Western blot films was obtained 
using a Bio-Rad model GS-670 Imaging Densitometer (Hercules, CA).  Percent 
of control was calculated by dividing the mean volume OD of the treatment group 
by the mean volume OD of the control group (the mean of two controls per 
experiment).  Differences within an experiment were detected using ANOVA and 
pairwise comparisons were made with Fisher's protected LSD (SuperANOVA 
version 1.11, Abacus Concepts Inc., Berkely, CA).  p < 0.05 was considered a 
significant difference between two groups.  The treatment experiments were 
repeated three times, and the TGFβ dose-response experiments were repeated 
four times.   All figures show the mean of the experimental replicates as a 
percent of the control level in each individual experiment.   
 
Results 
Presence of Brevican and ADAMTS4 in Enriched Astrocytes, Neurons and 
Microglia 
 The isoforms of brevican secreted from enriched cultures of astrocytes, 
neurons and microglia were examined utilizing Western blot.  In astrocyte and 
neuronal cultures, the full length 145 kD brevican core protein was found in 
conditioned medium (Fig. 3, top panel; Fig. 2B), yet the presence of core protein 
that contained CS chains, the predominant form found in adult rat brain tissue 
(Fig. 3, top panel, Fig. 2A), was highly variable and appeared in the medium in 
some cultures yet was absent in others (Fig. 3, lane NM top panel, higher, > 145 
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kD molecular weight and observed as a smear; Fig. 2A).  Relative to extracts of 
adult rat brain, little CS containing brevican is present in astrocyte cultures (Fig. 
3).  In lysates derived from astrocytes and neuronal cultures, the 145 kD core 
protein was present along with lower molecular weight isoforms that possibly 
represent the underglycosylated form of brevican (Viapiano et al. 2003) or 
brevican tethered to the membrane via a glycosylphosphatidylinositol (GPI)-
anchor (Seidenbecher et al. 1995) (Fig 3, top panel).  Since samples for these 
blots were whole cell lysates, it is unclear whether this "underglycosylated" form 
is extracellular brevican that is cell-associated or whether it is intracellular and is 
simply being processed in the secretory pathway.  The 55 kD N-terminal 
proteolytic cleavage fragment, thought to include products of both ADAMTS and 
MMP cleavage, was found exclusively in astrocyte and neuronal conditioned 
medium (the immunoreactivity in the neuronal medium lane above this band is 
cross-reactivity of the antibody with B-27 supplement required for medium in 
neuronal culture).  The presence of these specific isoforms was confirmed with 
their detection in extract from adult rat hippocampal tissue (Fig. 3 top panel, lane 
RT).  Likewise, the ADAMTS-derived cleavage fragment of brevican, EAVESE, 
was found in astrocyte and neuronal medium, but was absent in lysate (Fig. 3, 
middle panel; Fig. 2C).  Microglia showed a different pattern of expression of 
brevican and ADAMTS4 compared to neurons and astrocytes.  Brevican or its 
processed fragments were not found in microglial medium or lysate.  The major 
isoform of the ADAMTS4 protease is a 53 kD, N- and C-terminally truncated 
protein.  Interestingly, the activated isoform of ADAMTS4 (53 kD) was detected in 
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the cell lysate of microglia, neurons and astrocytes, but was absent from all 
medium (Fig. 3, bottom panel).  The 53kD isoform of ADAMTS4 was much less 
abundant in microglia, yet the 68kD, N-terminally (only) truncated form was 
present, in addition, to a 32 kD isoform that was also found in human 
recombinant ADAMTS4 (Fig. 3, bottom panel).   
 
Figure 3. Brevican, ADAMTS-cleaved brevican and ADAMTS4 expression in 
neural cultures. 
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Figure 3. Brevican, ADAMTS-cleaved brevican and ADAMTS4 expression in 
neural cultures.  Brevican, ADAMTS-cleaved brevican (anti-EAVESE) and 
ADAMTS-4 (top, middle and bottom panels, respectively) were detected by 
immunoblot in cultures of neurons, astrocytes and microglia.  Neuronal medium 
and cell lysate (NM and NL), astrocyte medium and cell lysate (AM, AL) and 
microglia medium and cell lysate (MM, ML) were examined.  Extract from adult 
rat hippocampal tissue prepared under the same conditions (RT) was the internal 
brevican positive control sample whereas human recombinant ADAMTS4 (HR) 
was utilized as a control for the ADAMTS4 immunoblot.  Intact core brevican was 
detected in neurons and astrocytes, but microglia apparently failed to express the 
protein.  The 55 kD (top panel) and ADAMTS-derived cleavage fragments 
(middle panel) were detected in neuronal and astrocyte medium only.  An 
activated 53 kD isoform of ADAMTS4 was detected in the cell lysate of all three 
cell types, but was not secreted into the medium, however, microglia processed 
the protease differently from cultures of enriched neurons and astrocytes (bottom 
panel). 
 
Treatment with Cytokines in Astrocyte Culture 
 In an effort to identify factors that regulate brevican secretion and 
cleavage, cultures of astrocytes were treated with phorbol myristate acetate 
(PMA) (100 nM), VEGF (25 ng/ 0.5 ml), TGFβ (25 ng/ 0.5 ml), and IL-1β (200 ng/ 
0.5 ml) and the core protein and cleaved fragments of brevican were quantitated 
using densitometry of the immunoreactive bands on Western blot (Fig. 4).  TGFβ, 
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but not other factors, significantly enhanced brevican levels (more than 12-fold) 
found in conditioned medium of astrocyte cultures (Fig. 4, upper and middle left 
panels, p <0.05).  This effect was dose-related (3.12, 6.25, 12.5 and 25 ng/ 0.5 
ml) with a minimal effective dose of 6.25 ng/ml TGFβ (Fig. 4, upper and middle 
right panels, p < 0.05).  However, in spite of the marked elevation in intact 
brevican in response to TGFβ, the cleaved N-terminal fragment (55 kD) was not 
significantly affected by treatment with any of the cytokines (Fig. 4, bottom 
panels).  Films with shorter exposures and less dense bands were used to 
quantitate the optical density of the 55 kD bands (not shown).  In addition, there 
was a trend for decreased immunoreactivity of the ADAMTS-derived, 55 kD, N-
terminal fragment in response to TGFβ (Fig. 5).  In particular experiments, this 
trend appeared to be dose-related (Fig. 5, upper right panel).   
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Figure 4. Levels of intact brevican (145kD) and the N-terminal total cleavage 
product of brevican (55 kD) in medium from cytokine-treated primary astrocyte 
cultures.  (Upper panels) Shown are representative blots of astrocyte medium 
from cultures treated with cytokines (left) or increasing doses of TGFβ (right) and 
probed with anti-brevican.  (Middle panels) Quantification of levels of full-length 
brevican when treated with PMA, VEGF, TGFβ and IL-1β (left) or increasing 
doses of TGFβ (right), demonstrating a significant increase in full length brevican 
after TGFβ treatment. (Lower panels) Quantification of levels of 55 kD brevican 
fragment in response to the same treatments as the middle panels. 
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Figure 5. Levels of ADAMTS cleaved brevican (55kD) in cytokine treated 
astrocyte cultures.  (Upper panels) ADAMTS cleaved brevican immunoreactivity 
(as measured by anti-EAVESE) in astrocyte culture medium when treated with 
cytokines (left panels), or increasing doses of TGFβ (right panels).  No significant 
change in the fragment was detected, however, a trend for a decrease in the 
level of the fragment was observed. 
 
 Since levels of the ADAMTS-derived fragment of brevican either were not 
changed in the face of large increases in core brevican or were actually 
decreased in response to TGFβ, it was of interest to determine whether this 
cytokine influenced the expression of the most abundant ADAMTS in the nervous 
system, ADAMTS4.  Neither TGFβ nor any of the other cytokines tested altered 
the levels of ADAMTS4 protein that were found in astrocyte cell lysate (Fig 6).  
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However, it may be that activity, rather than expression of the active protease 
was changed, and thus, a rather semi-quantitative measure of ADAMTS activity 
is the ratio of the content of the ADAMTS-derived fragment and the content of 
intact core brevican.   Interestingly, this ratio was markedly diminished after 
treatment with TGFβ (Fig. 7, upper panel), an effect that was dose-dependent 
(Fig. 7, lower panel).   
 
 
 
Figure 6. ADAMTS-4 protein levels in response to cytokine treatment.  (Upper 
panels) ADAMTS-4 immunoreactivity in astrocyte cell lysate after PMA, VEGF, 
TGFβ or IL-1β treatment (left) or increasing doses of TGFβ (right).  (Lower 
panels) There were no significant changes in ADAMTS-4 protein levels when 
treated with cytokines (left) or increasing doses of TGFβ (right). 
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Figure 7. Apparent ADAMTS activity in cytokine treated astrocyte cultures.  
ADAMTS activity is indirectly measured by examining the ratio of ADAMTS-
cleaved versus full length brevican.  (Upper panel) ADAMTS activity in cytokine 
treated astrocytes, demonstrating the marked reduction occurring with TGFβ 
treatment, but not with other treatments.  (Lower panel) Dose dependent 
decrease in activity in response to increasing doses of TGFβ. 
 
Discussion 
 Astrocytes are predominant in the production of many ECM proteins in the 
nervous system.  Astrocytes contribute to the formation of the basal lamina of the 
cerebrovasculature, and are a major cell type responsible for the production of 
ECM components that constitute perineuronal nets and the matrix of the neuropil.  
One purpose of this study was to characterize the brevican-containing matrix 
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present on astrocyte monolayers, since the ultimate intention is to use these 
astrocytes as a substrate for growth and maturation of neurons.  We have found 
that astrocytes and neurons in culture synthesize and secrete the 145 kD intact 
brevican core protein, a proportion of which is found in the medium and the 
remainder is associated with the cell lysate fraction.  It is not clear at this point 
whether core brevican in the lysate is actually found extracellularly and cell-
associated or whether it is intracellular, located in the secretory pathway.  Two 
additional isoforms were detected and found only in the lysate fraction.  These 
may be the underglycosylated and/or GPI-linked isoforms (Viapiano et al. 2003) 
(Seidenbecher et al. 1995).  Both these forms were found in lysate from primary 
cultures of rat cortical neurons as well.  Brevican has been identified in tissue 
culture previously as one study demonstrated the presence of brevican mRNA in 
cultures of cerebellar astrocytes, although the transcript was absent in rat 
cerebral cortical neurons in culture (Yamada et al., 1994).  More recently 
however, brevican protein was detected in cultures of cerebral cortical neurons 
associated with synaptic proteins (Seidenbecher et al., 2002).  Interestingly, in 
this study, only a small fraction of CS-bearing brevican protein was secreted from 
either astrocytes or neurons, which contrasts markedly with adult rat brain tissue, 
where greater than 50% of total brevican contains CS chains. (Fig. 3; Yuan et al., 
2002).  It may be that the cells that express glycosyl transferases necessary for 
adding the CS chains to brevican require further maturation, or that the factors 
required for this maturation are produced only in mixed cultures.   
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 Although both MMPs and the ADAMTSs are capable of cleaving brevican 
(and lecticans in general) into two fragments (Nakamura et al. 2000; Westling et 
al. 2002), the main protease responsible for the extracellular processing of 
brevican in vivo appears to be the ADAMTSs.  ADAMTS4 mRNA is expressed in 
many regions of the nervous system, it is markedly up-regulated in response to 
excitotoxic injury (Yuan et al. 2002) and may be a major protease involved in 
clipping the lecticans.  In primary cultures of rat astrocytes, the N-terminal 
cleavage fragment containing the G1 globular domain of brevican, whether the 
total G1 fragment or the ADAMTS-specific fragment, were found only in medium 
and not in the lysate fraction.  Since this N-terminal region contains a 
hyaluronan-binding domain, it suggests that hyaluronan was not part of any 
pericellular matrix that was assembled in these cultures.  In addition, since a 
portion of intact brevican was associated with the cell surface, it may be the 
brevican was bound via the C-terminal domain, possibly via binding to tenascin-R 
(Aspberg et al. 1997; Hagihara et al. 1999).  ADAMTSs are well known to be 
bound to the pericellular region in a variety of cell types in vitro (Kuno and 
Matsushima 1998), and immunoreactivity for ADAMTS4 in this study was absent 
from the medium but found at clearly detectable levels in the cell lysate fraction 
of astrocytes, neurons and microglia.   
 There are a host of ECM proteins, including the aggregating PGs, 
aggrecan (Bassols and Massague 1988), versican (Stokes et al. 2001) and 
neurocan (Asher et al. 2000), whose synthesis and secretion is induced by 
TGFβ, so it is not surprising that we observed a marked increase in the levels of 
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brevican in the medium of astrocytes in response to TGFβ.  Whereas TGFβ is 
protective and trophic in several systems and models of injury (Brandes et al. 
1991), others have demonstrated in particular that TGFβ was destructive toward 
cartilage and increased the synthesis and release of ADAMTS4, but not 
ADAMTS5, in fibroblast-like synoviocytes and human chondrocytes (Yamanishi 
et al. 2002; Moulharat et al. 2004).  In addition, infusing decorin, an inhibitor of 
TGFβ, into damaged spinal cord led to an 80% reduction in proteoglycan 
expression (Davies et al 2004) and improved the outcome of the injury.  In this 
study, TGFβ was a potent inducer of brevican production in the culture medium 
that may be the result of stimulated gene expression.  However, even in the 
presence of this marked elevation of the level of intact brevican, there was a 
trend for a decline in the production of the N-terminal proteolytic fragment after 
TGFβ.  Thus, when using the ratio of the ADAMTS-derived fragment of brevican 
and intact brevican as an estimate of ADAMTS activity, there was a dramatic 
decline in the apparent ADAMTS activity after TGFβ treatment of cultured 
astrocytes.  When measuring ADAMTS4 protein level, though, by Western blot, 
the levels were not changed.  However, several mechanisms might explain the 
decline in ADAMTS activity without a change in protein after TGFβ.  First, TGFβ 
has been shown to be a potent stimulator of tissue inhibitor of metalloproteinase-
3 (TIMP-3) production, and TIMP-3 is a potent endogenous inhibitor of ADAMTS 
activity.  Other TIMPs are either less potent or not effective in inhibiting ADAMTS 
activity (Kashiwagi et al. 2001).  Second, it may be that TGFβ altered the 
processing of ADAMTS4 by inhibiting a membrane type protease that converts it 
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to its lower molecular weight active form (Gao et al. 2004), although this 
alteration in processing should have been recognized by observing a higher 
molecular weight isoform of ADAMTS4 on Western blot.  Third, TGFβ may be 
inducing proteases or other factors that could sequester or degrade the fragment, 
such as carboxypeptidases that diminish its detection.  Finally, one cannot rule 
out the possibility that ADAMTS4 (or the sum of all active ADAMTSs) is saturated 
by its brevican substrate and increases in substrate concentration do not result in 
elevated product (fragment) simply because the protease was acting maximally 
at the lower concentration of substrate.  
 Nonetheless, these results demonstrate that brevican is secreted by 
astrocytes and neurons in culture, that TGFβ is a potent stimulator of brevican in 
astrocytes, and that TGFβ also attenuates ADAMTS cleavage of brevican.  
These findings suggest that TGFβ, which is often released in response to various 
injuries, may be non-permissive toward neural plasticity and regeneration.  Since 
intact brevican may stabilize synaptic networks (Hockfield et al. 1990), and 
because cleavage of brevican may loosen aggregates of ECM in the brain and 
produce favorable conditions for morphological plasticity (Yamaguchi 2000; Yuan 
et al 2002), it may be that TGFβ stabilizes these networks by diminishing the 
cleavage of brevican.  The mechanism of such a response remains to be 
elucidated. 
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Chapter 2: ADAMTSs (a disintegrin and metalloproteinase with thrombospondin 
motifs) Enhance Neurite Outgrowth through a Non-Proteolytic Mechanism 
Mediated by Extracellular Signal-Related Kinase1/2 
 
Abstract 
Aggregating proteoglycans (PG) bearing chondroitin sulfate (CS) side 
chains are well-known inhibitors of neural plasticity and associate with 
hyaluronan and tenascin-R to form a complex of extracellular matrix (ECM) in the 
central nervous system (CNS).  Chondroitinase treatment depletes PGs of their 
CS side chains and enhances neural plasticity including neurite extension.  Little 
is known about whether proteolytic cleavage of the core protein affects neural 
plasticity.  Several members of the ADAMTS (a disintegrin and metalloproteinase 
with thrombospondin motifs) family of metalloproteinases are glutamyl-
endopeptidases that cleave aggregating PGs.  The purpose of this study was to 
determine whether cleavage of aggregating PGs, especially brevican, by the 
ADAMTSs influences neurite outgrowth in cultured neurons.  Transfection of rat 
neurons with ADAMTS4 cDNA induced longer neurites, whether the neurons 
were grown on a monolayer of astrocytes that secrete inhibitory PGs or on 
laminin/poly-l-lysine substrate alone.  Even more surprising, the increase in 
process extension was also observed when neurons were transfected with an 
 36
expression vector construct coding for a proteolytically inactive, point mutant of 
ADAMTS4.  Addition of recombinant ADAMTS4 or ADAMTS5 protein to 
immature neuronal cultures similarly enhanced neurite extension.  Increases in 
the abundance of proteins phosphorylated on tyrosine residues and more 
specifically, the amount of phosphorylated extracellular signal-related kinase 
(ERK)1/2 (MAP kinase 42/44) immunoreactivity were detected shortly after the 
addition of recombinant ADAMTS4 to neurons.  Furthermore, ADAMTS-induced 
increases in neurite outgrowth were diminished by treatment with selective MAP 
kinase inhibitors.  These results demonstrate that ADAMTS4 enhances neurite 
outgrowth and does so likely via induction of signaling at the cell surface and 
activation of the MAP kinase cascade, an action that does not require the 
proteolysis by ADAMTS4. 
 
Introduction 
Injury to the central nervous system (CNS) is often debilitating and is 
compounded by little hope of recovery owing to the fact that once neural 
networks in the CNS are severed, they are difficult to re-establish.  
Predominantly, this is because the properties of myelin-associated proteins and 
other proteins that compose a glial scar impede the growth of axons toward their 
target.  The glial scar is an accumulation of reactive astrocytes and extracellular 
matrix (ECM) molecules such as chondroitin sulfate (CS)-substituted PGs, 
keratin and tenascin that inhibit the re-growth of axons and the migration of 
particular cell types into the damaged region of the brain (Davies et al., 1997; 
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Davies et al., 1999) (Laywell et al., 1992) (McKeon et al., 1991).  Indeed, the CS 
side chains of PG molecules are well-known to inhibit neurite outgrowth under a 
variety of in vitro and in vivo conditions (Silver and Miller, 2004; Carulli et al., 
2005).   
The family of hyaluronic acid-binding PGs with CS side chains that 
regulate cell adhesion, migration and neurite outgrowth in the CNS are termed, 
lecticans, and include aggrecan, brevican, neurocan and versican.  Large, 
sulfated, highly negatively-charged CS chains are covalently bound to the central 
domain of lecticans and discourage growth cone motility and neurite elongation, 
however, when these glycosaminoglycan polymers are removed from the core 
proteins by chondroitinase treatment (Pizzorusso et al., 2002), a significant 
degree of inhibition is retained by versican (Schmalfeldt et al., 2000), but not by 
brevican (Miura et al., 2001).  The enduring biological action may be inherent to 
the core PG protein itself or it may result from interactions with other ECM 
molecules such as hyaluronan or tenascin-R.  Intermolecular interactions among 
lecticans, hyaluronan and tenascin form a mesh-like lattice in the matrix of the 
CNS that could inhibit neural plasticity (Fig. 8, A).  Thus, to facilitate plasticity, 
there should be a means to relieve the inhibition afforded by the PG.  The 
absence of an endogenous chondroitinase to remove CS chains is a major 
limiting factor, so taking advantage of a mechanism that occurs in vivo may be a 
more feasible way to re-establish plasticity in the brain.  One such possibility 
would be via increased expression and activation of endogenous proteases that 
cleave the PG, a mechanism that would loosen the association and interaction 
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among the matrix components that inhibit plasticity, and allow for enhanced 
neural growth (Fig 8, B). 
 
Figure 8. Lectican-tenascin-hyaluronan matrix complex in the CNS and lectican 
cleavage by ADAMTSs. 
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Figure 8. Lectican-tenascin-hyaluronan matrix complex in the CNS and lectican 
cleavage by ADAMTSs.  (A), Intact complexes of extracellular matrix form an 
inhibitory boundary toward neurite outgrowth by hyaluronic acid binding to the N-
terminus, tandem repeats of the lecticans and tenascin binding to the C-terminus 
of the lecticans.  (B), Cleavage of lectican by an ADAMTS loosens the stable, 
matrix network, increasing fluidity and potentially allowing for increased plasticity.  
(C, D), Cleavage of the lectican, brevican, by human recombinant ADAMTSs.   
 
Proteoglycans were purified from rat brain extracts contained in fractions 
eluted from a DEAE column with 1 M NaCl.  Lectican-containing fractions were 
incubated with active ADAMTSs, or heat-inactivated protease (Inactive), 
subjected to SDS-PAGE, and probed with anti-brevican antibody (C) to reveal 
holoproteins and the N-terminal cleavage product or with anti-EAVESE antibody 
to selectively reveal the N-terminal fragment that contains the EAVEAE 
neoepitope exposed by ADAMTS-cleavage of brevican (D).  "Control" lane 
shows brevican immunoreactivity as a smear at a molecular weight of >145 kD.  
Samples containing inactive ADAMTS show little cleavage, whereas brevican 
substrate incubated with human recombinant ADAMTSs 1, 4 and 5 (25 nM) for 3 
hours reveal an abundance of the 55 kD, N-terminal cleavage fragment (C) that 
is observed when probed with antibody selective for the ADAMTS-cleaved 
fragment (D). 
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The ADAMTSs (a disintegrin and metalloproteinase with thrombospondin 
motifs) are multi-domain, metalloproteinases that have notable roles in 
angiogenesis, coagulation, collagen processing, cell migration and arthritis.  
Several of the ADAMTSs are glutamyl-endopeptidases that cleave lecticans.  
These secreted proteases share similar functional domains, including a pro-
domain, metalloproteinase, disintegrin-like, cysteine-rich and spacer domains (for 
review, see (Apte, 2004)).  Activation of the pro-protease likely occurs by furin-
mediated cleavage of the pro-domain at the N-terminus, and further C-terminal 
truncations are necessary to fully activate the enzyme (Wang et al., 2004) (Gao 
et al., 2004a) (Kuno et al., 1999).  The interaction of the ADAMTS domains with 
their substrates is complex and may involve binding via the thrombospondin type 
1 motif and/or sequences in the C-terminal spacer or cysteine-rich region of the 
molecule (Kuno and Matsushima, 1998; Tortorella et al., 2000; Flannery et al., 
2002; Kashiwagi et al., 2004).   
ADAMTSs, especially ADAMTS 1, 4, 5, and 9, are expressed in brain 
(Hurskainen et al., 1999; Yuan et al., 2002; Jungers et al., 2005) (our 
unpublished observations), and it is interesting that each of these proteases is 
active in cleaving PGs.  Several of the ADAMTSs have been shown to be 
elevated in human neurodegenerative disease and animal models of brain injury.  
ADAMTS1, but not ADAMTS5, appears to be up-regulated in Down syndrome, 
Pick’s disease and Alzheimer’s disease (Miguel et al., 2005).  The expression of 
ADAMTS4 and ADAMTS1 mRNA was markedly elevated in the hippocampus of 
rats in response to kainate-induced excitotoxic lesion (Yuan et al., 2002), and 
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ADAMTS1 was increased in the spinal cord of rodents having undergone 
axotomy (Sasaki et al., 2001), indicating that these proteases may be increased 
in response to injury or during an inflammatory response.   
Anecdotal, but growing evidence has supported the notion that 
metalloprotease activity is important in mechanisms of neural plasticity.  Nerve 
growth factor treatment of PC-12 cells results in MMP-3 expression (Machida et 
al., 1989; Fillmore et al., 1992), and MMP-3 is essential in promoting PC12 cell 
growth cone invasiveness through an artificial basal lamina (Nordstrom et al., 
1995).  More recently, excitotoxic lesion in the brain was shown to result in the 
expression of MMP-9 in the hippocampus (Zhang et al., 1998; Szklarczyk et al., 
2002) and neuritic sprouting observed in the dentate gyrus after a lesion of 
entorhinal cortex was blocked by administration of a broad spectrum MMP 
inhibitor (Reeves et al., 2003).  These actions certainly point toward a role for the 
matrix-degrading metalloproteinases in neural plasticity.  We recently 
demonstrated that active ADAMTSs which cleave the lectican, brevican, are 
elevated in the dentate gyrus terminal zone during the period of neuritic sprouting 
after entorhinal cortex lesion (Mayer et al., 2005).  Taken together, these studies 
support the hypothesis that remodeling of ECM may be an important component 
in processes of neural and synaptic plasticity.  Thus, the purpose of this study 
was to more directly test the hypothesis that lectican-degrading activity may 
promote neurite outgrowth over an ECM that contains inhibitory PGs.  We grew 
primary cultured neurons that were either secreting ADAMTS4 via a transfected 
expression vector or were exposed to ADAMTSs by direct addition of 
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recombinant protein to the media.  In some of these experiments, neurons were 
grown on an astrocyte monolayer that had previously been shown to deposit 
brevican in the ECM (Hamel et al., 2005; John et al., 2006).  Surprisingly, our 
results show that ADAMTS4, and other ADAMTSs, promote neurite outgrowth in 
primary cultured embryonic neurons via a mechanism that is independent of its 
proteolytic activity.  In addition, intracellular signaling, appropriate for neurite 
outgrowth, is induced in ADAMTS-treated neurons.   
 
Materials and Methods 
PG degradation assay 
 Highly negatively charged molecules, including PGs, present in whole rat 
brain extracts were bound and eluted from a DEAE matrix as described (Yamada 
et al., 1994).  Briefly, rat brain tissue (1g) was placed in 10 ml, ice cold, 4 mM 
HEPES pH 8.0, 0.15 mM NaCl, 0.1% Triton-X-100 containing 2 mM 1,10 
phenanthroline (Sigma, St. Louis) and protease inhibitor cocktail (set III, 
Calbiochem, San Diego).  The tissue was disrupted in a teflon-glass 
homogenizer and the whole extract centrifuged at 30,000 x g for 30 min at 4˚C.  
The supernatant was removed, diluted 1:1 with 50 mM Tris-HCl, 0.15 M NaCl, 
0.1% Triton-X-100, and passed over a DEAE column pre-equilibrated with the 
same buffer at a flow rate of less than 0.5 ml per minute.  The flow through was 
collected, passed over the column again, and bound proteins were eluted with 5 
column volumes of consecutive buffers containing 50 mM Tris-HCl pH 8.2, 0.15 
M NaCl, 0.1% Triton-X-100, then 50 mM Tris-HCl pH 8.2, 0.25 M NaCl, 6 M urea, 
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0.1% Triton-X-100, and fractions containing PGs were eluted with 50 mM Tris-
HCl pH 8.2, 1.0 M NaCl.  PG-containing fractions were dialyzed against water for 
24 h in SpectraPor 6000-8000MWCO (Millipore, Billerica, MA) membrane, the 
samples concentrated on a speed-vac and aliquoted.  Total protein was 
measured in the samples and it was 1.3 µg/µl.  DEAE-purified PG samples were 
incubated with 25 nM recombinant ADAMTS1 (Chemicon), ADAMTS4 or 
ADAMTS5 (expressed at Roche Biosciences, Palo Alto) (diluted in 10 mM Tris-
HCl, 0.15 M NaCl, and 10mM CaCl2) for three hours at 37˚C.  ADAMTS4 and 
ADAMTS5 were inactivated by heating to 95˚C for thirty minutes and were 
included as controls.  After a three hour incubation period, beta-mercaptoethanol-
containing SDS-PAGE sample buffer was added to the samples, the samples 
were heated at 95˚C for 4 minutes, and subjected to SDS-PAGE and Western 
blotting.  Membranes were probed with mouse anti-brevican (BD Biosciences, 
San Jose) at 1:1000 and anti-EAVESE (Hamel et al., 2005) at 1:100, and primary 
antibody detected with anti-mouse or anti-rabbit IgG conjugated to horse-radish 
peroxidase (Chemicon, Temecula, CA), and signal detected using SuperSignal 
chemilluminscence substrate (Pierce, Rockford, IL).   
 
Primary cell cultures 
Primary cultures of astrocytes were prepared from whole brain (minus 
cerebellum) of postnatal day 1-3 Sprague-Dawley (SD) (Harlan, Indianapolis) rat 
pups in Dulbecco's Modified Eagles Medium containing 10% horse serum and 
2.5% fetal calf serum as described (Hamel et al., 2005).  Astrocytes were grown 
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in 100mm tissue culture dishes pre-coated with 100 µg/ml poly-L-lysine for seven 
days until confluent.  The cells were disrupted with trypsin and plated at 1x106 
cells on 22 mm glass coverslips (Fisher Scientific, Pittsburgh) pre-coated with 
500µg/ml poly-l-lysine (Sigma).  Seven days later, the astrocytes had formed a 
confluent monolayer and at this time, the cells were used as a neuronal growth 
substrate.  Freshly prepared, trypsinized cells from cerebral cortex of embryonic 
day 18 SD pups  (Hamel et al., 2005) were transfected with ADAMTS4 
expression vector or empty control vector and 1x106 cells were plated either 
directly on the confluent astrocyte monolayer or onto glass coverslips pre-coated 
with 500 µg/ml poly-L-lysine and 25 µg/ml mouse laminin (Invitrogen, Carlsbad).  
Twenty-four hours after plating the neurons, plating medium that consisted of 
Dulbecco's Modified Eagles Medium plus 10% fetal calf serum was replaced with 
Neurobasal serum-free medium (Invitrogen) containing B-27 defined supplement 
(Invitrogen), 0.5mM Glutamax II (Invitrogen-Gibco, Carlsbad) and 25µM 
glutamate, and containing 1% antibiotic/antimycotic (Invitrogen-Gibco).  Neurons 
plated either on an astrocyte monolayer or in the absence of the monolayer were 
cultured for seven days. 
 
Transfection by electroporation 
 For the experiments described above, plasmid expression constructs of 
ADAMTS4 were made for transfection into primary rat cells trypsinized from 
cerebral cortex.  A cDNA for ADAMTS4 (Gao et al., 2002), and an inactive point 
mutant of ADAMTS4 362 (E→Q) (Gao et al., 2004a) that were inserted into 
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pcDNA (Invitrogen), were restricted with Xba I and Kpn I (Promega, Madison), 
the ADAMTS4 (or mutant) fragment purified from an agarose gel and ligated into 
linearized pCMS plasmid, a dual promoter vector that expresses enhanced green 
fluorescent protein (EGFP) driven by SV40 (Clontech, Mountain View, CA).  After 
cells from cerebral cortex of E18 SD pups were isolated, 5x106 cells were 
centrifuged and resuspended in 100µl rat nucleofector solution (Amaxa 
Biosystems, Gaithersburg, MD).  The cells were transferred to a cuvette and 
pCMS, pCMS-ADAMTS4 or pCMS-ADAMTS4 mutant were added and the 
cuvette subjected to electric current using the Nucleofector electroporator 
(Amaxa Biosystems) with either the O-03 or G-13 time and current pre-
programmed by the manufacturer.  Immediately after transfection, 500µl of pre-
warmed, 37°C Dulbecco's Modified Eagles Medium with 10% fetal calf serum 
was added to the cell suspension, and the cells were transferred to a sterile 
microcentrifuge tube until plating.  The transfected neurons were plated on glass 
coverslips pre-coated with the laminin/poly-L-lysine substrate or they were 
allowed to adhere directly to a previously cultured, live astrocyte monolayer.  
Neurons were allowed to extend neurites for seven days.  After this time, cells 
were washed one time in PBS, fixed in 4% room temperature paraformaldehyde 
for twenty minutes, and washed an additional three times with PBS.  Transfected 
cells were visualized under epifluorescence using a Zeiss Axioskop microscope 
interfaced with an Axiocam (Zeiss, Thornwood, NY) digital camera and images 
were obtained  with Openlab software (version 3.1.4, Improvision, Lexington, 
MA).  For all images, the brightness and contrast were adjusted equally and 
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consistently for images within a single experiment, and converted to grayscale 
using Adobe Photoshop (Version 8.0, San Jose). 
 
Data collection and statistical analysis – transfection experiments 
ImageJ software (Version 1.33u, NIH, Bethesda) was utilized to manually 
trace primary and secondary neurites to determine overall mean length of 
neurites per neuron and mean length of the longest neurite for each neuron.  A 
primary neurite was defined as a neurite that sprouted directly from the soma and 
was at least two times the diameter of the cell body.  A secondary neurite was 
defined as any neurite that branched from a primary neurite.  Numbers of primary 
and secondary neurites were also recorded.  The mean longest neurite was 
calculated by averaging the values of the longest neurite for each neuron 
measured, whereas the overall mean length of primary neurites was calculated 
by averaging values of every primary neurite measured.  Secondary neurites 
were analyzed similarly.  Means of experimental groups were statistically 
compared using ANOVA and pair-wise comparisons were made with Tukey-
Kramer post-hoc test (SuperAnova, v 1.11, Abacus Concepts, Berkeley).  A 
p<0.05 was considered a significant difference between groups.  Separate litters 
of rat pups were used to obtain cells for each of the three experiments. 
 
ADAMTS4 protein treatment 
 Neurons grown at  2.5x105 cells per well were cultured on 22 mm glass 
coverslips for six days and treated at 2 and 5 days in vitro with human 
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recombinant ADAMTS4 orADAMTS5.  Purified recombinant ADAMTS4 and 5 
were provided by Roche Biosciences.  Recombinant protein was diluted in 
Neurobasal medium plus 0.1% bovine serum albumin (BSA) and syringe filtered 
to sterilize.  BSA was added to prevent adherence of the recombinant protein to 
the filter.  Each of the ADAMTS protein preparations contained low, but 
detectable levels of endotoxin using the LAL assay (Cambrex, Walkersville, MD) 
that were comparable to the BSA controls.  Control wells received a matched 
volume of filtered Neurobasal medium plus 1% BSA.  Untreated controls were 
also measured in some experiments. At six days in vitro, neurons were fixed with 
4% paraformaldehyde and processed for immunohistochemistry.   
 
Immunohistochemistry 
 Neuronal cultures fixed as described above were incubated for one hour in 
blocking buffer containing 10% normal goat serum (NGS), 0.3% triton-X-100 and 
1M lysine in PBS at room temperature.  Cells were incubated overnight at 4˚C in 
dilution buffer (PBS, 10% NGS, 0.3%Triton-X-100) containing mouse anti-
microtubule associated protein-2 (Chemicon) diluted to 1:200.  The cells were 
washed three times in PBS and Alexa Fluor goat anti-mouse IgG fluorescent 
secondary antibody (Invitrogen) was incubated at a concentration of 1:500 for 1 h 
and the coverslips washed three times in PBS.  Next, the coverslips were 
incubated with a fluorescent-tagged, actin binding protein, Alexa-Fluor 488 
phalloidin (Molecular Probes/Invitrogen), at a dilution of 1:500 in 2% NGS and 
0.3%Triton-X-100 in PBS for 45 minutes at room temperature, followed by an 
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additional three rinses in PBS.  The coverslips were then mounted on slides with 
Vectashield (Vector Laboratories, Burlingame, CA) fluorescent mounting medium 
and the cells were visualized with epifluorescence.  Neurons were photographed, 
brightness and contrast of all photomicrographs were enhanced equally, and 
images converted to grayscale using Adobe Photoshop. 
 
Data collection and statistical analysis – protein treatment 
Due to a higher density of neurites compared to the transfection 
experiments, it was impossible to discern individual neurites to make length 
measurements.  Thus, neurites from a group that was blinded from the 
experimenter were traced on a new layer in Adobe Photoshop.  The background 
layer containing the photomicrograph was deleted, leaving the tracings, and 
ImageJ software was utilized to calculate the area of the image occupied by the 
neurite tracings.  This area was divided by the number of neurons in the field 
image, generating µm2 of neurite signal per neuron.  A mean was calculated for 
the area occupied by neurites per neuron for several images and differences 
between the means were determined by ANOVA and the Tukey-Kramer multiple 
comparison test.  A p < 0.05 was considered a statistically significant difference 
between groups.   
 
Phosphotyrosine and ERK1/2 analysis 
 Neurons were cultured for five days in vitro and treated with 50nM 
ADAMTS4.  At 20, 40 and 60 minutes after addition of ADAMTS4, 20mM Tris-
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HCl, 5mM EDTA, 1% Triton-X-100, and protease inhibitor cocktail set III 
(Calbiochem) were added to cells for fifteen minutes on ice, the extract scraped 
from the dish, centrifuged and stored at -80˚ C.  Neuronal lysates were subjected 
to Western blot analysis on 10% Tris-glycine SDS-PAGE gels, and the proteins 
were transferred onto Immobilon membranes (Millipore).  Membranes were 
probed with rabbit anti-ERK1/2, rabbit anti-phospho-ERK1/2 (Chemicon) and/or 
mouse anti-phosphotyrosine (BD Biosciences) and the presence of primary 
antibody was detected with HRP conjugated to secondary antibody as described 
for anti-brevican and anti-EAVESE above.  The same blots were re-probed for 
phosphotyrosine and ERK analysis and densitometric measures of the 
immunoreactive protein bands were obtained from the ERK blots and the ratio of 
activated phospho-ERK1/2 was calculated by dividing phospho-ERK protein 
band density by total ERK1/2 band density.  The time at which the maximum 
stimulation of ERK1/2 was observed was somewhat variable between 
experiments.  Thus, representative blots and representative densitometric 
measures are shown in Fig. 13 and 14, with similar, but not identical, results 
seen in the replicate experiments. 
 
MAP kinase inhibition  
 Neurons were treated with MAP kinase inhibitors thirty minutes before the 
addition of 50nM ADAMTS4 to the cultures as described above.  PD98059, 
(Tocris, Ellisville, MO), a selective inhibitor of activated ERK1/2, and U0126 
(Tocris), an inhibitor of active and inactive ERK1/2, were added at 10, 25 and 
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50µM before the addition of 50nM ADAMTS4.  U0124 (Tocris), the inactive 
analog of U0126, was used as a negative control at 10, 25 and 50µM as well.  
Cultures were treated and incubated as described above and images of neurons 
were captured, processed and examined in the same manner as in the ADAMTS 
protein treatment experiments. 
 
Results 
Degradation of purified PG by recombinant ADAMTSs 
 To ensure that the human recombinant ADAMTS proteases used in these 
experiments were effective in degrading brevican purified from rat brain, human 
recombinant ADAMTS1, ADAMTS4 and ADAMTS5 were incubated with DEAE-
extracted PGs.  Soluble homogenate of rat brain was applied to a DEAE column 
and highly negatively-charged species were eluted with 1 M NaCl.  These 
proteins were incubated with active or heat-inactivated preparations of the 
human recombinant ADAMTSs.  At the end of a 3 h incubation period with 25 nM 
of each recombinant ADAMTS, the samples were subjected to Western blot for 
brevican.  Brevican detected in DEAE-eluant in the absence of recombinant 
protease was observed as a smear > 145 kD representing isoforms bearing 
various numbers of CS chains (Fig. 8C, control).  Incubation of DEAE eluants 
with ADAMTS 1, 4 and 5 resulted in cleavage of brevican and the appearance of 
a 55kD N-terminal fragment (Fig. 8C).  This same 55 kD fragment was detected 
when the membrane was probed with a rabbit antibody that recognizes the 
ADAMTS-specific, C-terminal, neoepitope rat sequence, EAVESE, exposed on 
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the N-terminal fragment of ADAMTS-cleaved brevican (Fig. 8D) (Hamel et al., 
2005). After cleavage by each protease, the abundance of intact brevican was 
clearly diminished.  Proteolytic activity was lost or significantly attenuated when 
the ADAMTS4 or ADAMTS5 preparations were heat inactivated prior to 
incubation with substrate (Fig. 8C and 8D).  These results demonstrate that each 
of the recombinant preparations of the ADAMTSs was proteolytically active. 
Neurite extension in primary rat neurons transfected with ADAMTS4 cDNA grown 
on an astrocyte monolayer  
 Since monolayers of rat astrocytes express brevican that remains 
associated with the cell layer (Hamel et al., 2005), we were interested in 
determining whether overexpression of ADAMTS4 would stimulate cleavage of 
brevican and/or other PGs present in the astrocyte monolayer matrix and thus, 
promote neurite outgrowth in cells expressing ADAMTS4.  To accomplish this, 
primary rat neurons were transfected with pCMS-EGFP vector that contained a 
human ADAMTS4 cDNA insert.  Other neurons were transfected with pCMS-
EGFP plasmid without the ADAMTS4 insert.  The transfected neurons were 
plated on mature astrocyte monolayers, ie. two-week old cultures of postnatal 
day three astrocytes that had been sub-cultured one time.  Seven days after 
plating, photomicrographs of fixed cultures were imaged (Fig. 9A, 9C) and 
tracings were made of neurites (Fig. 9B, 9D).  Autofluorescence attributed to the 
astrocyte monolayer can be seen in the photomicrographs (Fig. 9A, 9C).  
Neurons transfected with ADAMTS4 cDNA more readily penetrated the astrocyte 
matrix, and extended 20 – 40% longer primary and secondary neurites as 
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compared to neurons transfected with empty vector (p ≤ 0.05) (Fig. 9E).  There 
was no statistically significant difference in the number of primary neurites 
between control empty vector transfected neurons and those transfected with 
pCMS-EGFP ADAMTS4 cDNA, however, the number of secondary neurites was 
significantly increased in ADAMTS4-transfects (p ≤ 0.05) (Fig. 9E, bottom right 
panel).  Neurons from multiple coverslips taken from a single culture were utilized 
in this experiment, and similar results obtained in a replicate experiment.   
 
Figure 9. ADAMTS4 cDNA induces neurite outgrowth in neurons grown on 
astrocyte monolayers. 
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Figure 9. ADAMTS4 cDNA induces neurite outgrowth in neurons grown on 
astrocyte monolayers.  Primary cortical neurons transfected with empty pCMS 
vector or pCMS inserted with ADAMTS4 cDNA were grown on a previously 
prepared astrocyte monolayer for 7 days.  Representative photomicrographs 
depict neurons transfected with empty pCMS (A) or with the ADAMTS cDNA 
insert (C).  Photographs were taken of the fluorescing neurons and neurites were 
traced as a measure of neurite outgrowth (B, pCMS; D, pCMS-ADAMTS4).  
Means ± SEM of traced neurons reveal ADAMTS4 increases several parameters 
of neurite outgrowth including the mean longest primary and secondary neurites, 
overall mean primary and secondary neurites and number of secondary neurites 
(* signifies p ≤ 0.05 compared to control pCMS vector alone).  No significant 
difference was observed in the mean number of primary neurites in response to 
ADAMTS4 cDNA transfection (p > 0.05).  A single independent neuronal culture 
was utilized to measure 117 primary and 84 secondary neurites from 50 empty 
pCMS-transfected neurons and 127 primary and 124 secondary neurites from 37 
pCMS-ADAMTS4-transfected neurons.  Similar data was obtained when the 
experiment was repeated.  Scale bars, 50µm. 
 
Neurite extension in primary rat neurons transfected with ADAMTS4 cDNA grown 
directly on substrate without an astrocyte monolayer  
 If ADAMTS4 was proteolytically degrading a substrate on the astrocyte 
monolayer, releasing the neurites from exposure to the inhibitory matrix, then 
neurons transfected with ADAMTS4 cDNA and neurons transfected with empty 
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vector should extend neurites equally as well when grown directly on plastic, in 
the absence of an astrocyte-derived ECM.  To test this notion, neurons were 
transfected as above, plated directly on poly-L-lysine/laminin-coated coverslips, 
and allowed to extend neurites (Fig. 10).  Interestingly, these sets of neurons 
exhibited neurite growth behavior similar to that observed when neurons were 
grown on the astrocyte monolayer.  Neurons overexpressing ADAMTS4 (Fig. 
10C, D) extended longer neurites as compared to control transfects (Fig. 10A, B) 
when grown on the poly-L-lysine/laminin substrate.  ADAMTS4 overexpression 
induced significant increases in all parameters measured (Fig. 10E, p ≤ 0.05), in 
this case, including the number of primary and secondary neurites.  A single, 
independent neuronal culture generated the neurons used in this experiment, 
and similar results obtained in a replicate experiment.  
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Figure 10. ADAMTS4 cDNA induces neurite outgrowth in neurons grown on a 
poly-L-lysine/laminin substrate. 
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Figure 10. ADAMTS4 cDNA induces neurite outgrowth in neurons grown on a 
poly-L-lysine/laminin substrate.  Primary cortical neurons transfected with empty 
pCMS vector or pCMS inserted with ADAMTS4 cDNA were grown on poly-L-
lysine/laminin coated coverslips in the absence of an astrocyte monolayer for 7 
days.  Representative photomicrographs depict neurons transfected with empty 
pCMS (A) or with the ADAMTS cDNA insert (C).  Photographs were taken of the 
fluorescing neurons and neurites were traced as a measure of neurite outgrowth 
(B, pCMS; D, pCMS-ADAMTS4).  Means ± SEM of traced neurons reveal 
ADAMTS4 induced statistically significant (* signifies p ≤ 0.05 compared to 
pCMS vector alone) increases in several parameters of neurite outgrowth 
including the mean longest primary and secondary neurites, overall mean 
primary and secondary neurites and the number of primary and secondary 
neurites.  112 primary and 48 secondary neurites from 45 empty pCMS-
transfected neurons and 136 primary and 107 secondary neurites from 44 
pCMS-ADAMTS4 transfected neurons derived from a single independent 
neuronal culture were analyzed.  Similar data was obtained when the experiment 
was repeated.  Scale bars, 50µm. 
 
Effects of ADAMTS4 on neurite outgrowth are independent of proteolysis 
 To more directly determine whether the proteolytic action of ADAMTS4 
was leading to increases in neurite outgrowth, transfection experiments were 
carried out again with an experimental group that was transfected with a pCMS 
construct that contained an ADAMTS4 cDNA bearing a point mutation in the 
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protease (Fig. 11, inactive ADAMTS4 mutant).  This cDNA encodes a protein 
with a single amino acid substitution 362 (E→Q) in the catalytic domain resulting 
in an inactive protease, yet it contains all other functional domains of ADAMTS4.  
Quite surprisingly, neurons transfected with either active ADAMTS4 cDNA or 
neurons transfected with proteolytically inactive ADAMTS4 cDNA extended 
longer neurites in the absence of an astrocyte monolayer.  Representative 
photomicrographs show increases in neuritic growth (Fig. 11A, B: control; 11C, 
D: ADAMTS4; 11E, F: inactive ADAMTS4 mutant).  Transfection with either the 
active or inactive ADAMTS4 construct resulted in enhanced length of the longest 
primary and secondary neurites, and the mean length of all primary and 
secondary neurites.  (Fig. 11G).  There was even a modest, but significant 
increase in the mean length of primary neurites in neurons transfected with the 
inactive ADAMTS4 mutant, compared to the wild-type ADAMTS4 cDNA (Fig. 
11G, top middle panel).  A single independent neuronal culture was used in this 
experiment, and similar results obtained in a replicate experiment.  
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Figure 11. An inactive mutant ADAMTS4 cDNA enhances neurite outgrowth. 
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Figure 11. An inactive mutant ADAMTS4 cDNA enhances neurite outgrowth.  
Primary cortical rat neurons transfected with empty pCMS vector, pCMS inserted 
with ADAMTS4 cDNA, or pCMS vector inserted with an inactive mutant form of 
ADAMTS4 cDNA were grown on poly-L-lysine/laminin coated coverslips in the 
absence of an astrocyte monolayer for 7 days.  Due to a point mutation in the 
catalytic domain (362 E→Q), this ADAMTS4 protein possesses the same 
structural domains as native ADAMTS4, but lacks any proteolytic capacity.  
Representative photomicrographs depict pCMS (A), pCMS-ADAMTS4 (C) and 
pCMS inactive ADAMTS4 mutant (E) expressing neurons.  Photographs were 
taken of the fluorescing neurons and neurites were traced as a measure of 
neurite outgrowth (B, pCMS; D, pCMS-ADAMTS4, F, pCMS inactive ADAMTS4 
mutant).  Means ± SEM of traced neurons reveal ADAMTS4 and inactive 
ADAMTS4 mutant induced statistically significant (* signifies p ≤ 0.05 compared 
to pCMS vector alone) increases in several parameters of neurite outgrowth 
including the mean longest primary and secondary neurites, overall mean 
primary and secondary neurites and the number of secondary neurites.  There 
was an additional increase in the mean length of primary neurites of neurons 
transfected with pCMS inactive ADAMTS4 mutant cDNA compared to neurons 
transfected with pCMS-ADAMTS4 cDNA, (** signifies p ≤ 0.05 compared to 
pCMS-ADAMTS4).  No significant differences (p > 0.05) were observed in the 
mean number of primary neurites in response to ADAMTS4 cDNA transfection.  
A single independent neuronal culture was utilized and 288 primary and 181 
secondary neurites from 111 empty pCMS-transfected neurons were examined.  
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207 primary and 171 secondary neurites from 70 pCMS-ADAMTS4-transfected 
neurons were measured, and 325 primary and 316 secondary neurites from 129 
pCMS-inactive ADAMTS4-transfected neurons were quantified.  Similar data was 
obtained when the experiment was repeated.  Scale bars, 50µm. 
 
Effect of recombinant ADAMTSs on neurite outgrowth 
 To test the effects of ADAMTS4 protein on neurite extension and 
potentially confirm the results seen with transfection, increasing concentrations of 
human recombinant ADAMTS4 were added to the medium of neurons at 2 and 5 
DIV and neurite length measured at 8 DIV.  Neurons were also treated with 
ADAMTS5 to determine whether this was an effect selective to ADAMTS4.  Each 
recombinant protein was diluted with BSA in culture medium and filter sterilized 
prior to addition to the culture.  Control wells consisted of untreated neurons and 
neurons treated with filtered medium and BSA (Fig. 12B, C) to ensure that the 
BSA was not affecting neurite outgrowth.  At 8 DIV, neurons were 
immunostained with microtubule-associated protein-2 and stained with phalloidin, 
images collected, and the lengths of neurites traced.  Compared to the 
transfection experiments, where low numbers of neurons were visible due to low 
transfection efficiency, all neurons were stained and visible with dense networks 
of neurites. For quantification, all neurites were traced in an individual field, and 
the "area occupied by neurite tracing" calculated.  When divided by the number 
of neurons in the field, it resulted in the area occupied by neurite tracing per 
neuron (µm2 tracing/neuron).   
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The addition of BSA in culture medium had no significant effect on neurite 
outgrowth compared to untreated cultures of neurons.  When neuronal cultures 
were treated with ADAMTS4, there was a dose-dependent increase in neuritic 
growth, with a statistically significant increase at 10 (Fig. 12D, E) and 50nM 
ADAMTS4 (Fig. 12A, F and G, p ≤ 0.05).  ADAMTS5, a member of this protease 
family not highly expressed in the nervous system, also significantly increased 
growth of neurites compared to control cultures (Fig. 12A, H and I, p ≤ 0.05). 
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Figure 12. Human recombinant ADAMTS4 induces neurite outgrowth. 
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Figure 12. Human recombinant ADAMTS4 induces neurite outgrowth.  
Representative photomicrographs and tracings are shown of primary cortical rat 
neurons grown on poly-L-lysine/laminin and treated with ADAMTS4 at 1, 10 (D,E) 
and 50nM (F,G) and ADAMTS5 at 10nM (H,I) or culture medium containing BSA 
(B,C) at days 2 and 5 of culture and neurite outgrowth measured at day 6.  At the 
end of culture, neurons were visualized by using anti-microtubule associated 
protein-2 immunocytochemistry and the Alexafluor 488-conjugated actin binding 
protein, phalloidin.  The photomicrographs (B,D,F,H) were converted to grayscale 
and neurites traced (C,E,G,I).  Data was calculated by dividing the area of the 
photograph occupied by neurite signal (µm2) divided by number of neurons in the 
field to generate mean ± SEM (µm2/neuron) that are shown in panel A.  
Treatment with ADAMTS4 resulted in a dose-dependent increase in neurite 
outgrowth (see panel A) and 10nM ADAMTS5 also significantly increased neurite 
outgrowth (* p ≤ 0.05 compared to untreated or medium + BSA treated wells).  
Three separate cultures were utilized in these experiments, with at least 10 fields 
in total for each treatment group, representing over 1,000 neurons for each 
group.  Scale bars, 100µm. 
 
Modulation of tyrosine phosphorylated proteins in response to ADAMTS4 
 Since ADAMTS4 appears to exert its effects on neurite outgrowth 
independent of its proteolytic activity, it is possible that ADAMTS may be 
signaling the cell by binding and acting at the cell surface.  Significant evidence is 
available showing that ADAMTS protein is localized to the ECM and cell surface 
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(Kuno and Matsushima, 1998; Kuno et al., 1999; Gao et al., 2004a).  Since 
neurite outgrowth has been shown to be mediated in part by tyrosine kinase 
signaling, neurons treated with ADAMTS4 were examined for elevated 
abundance of intracellular proteins containing phosphorylated tyrosine residues 
using an anti-phosphotyrosine antibody in neuronal lysates.  Neurons were 
treated with 50nM ADAMTS4 and extracted after 20, 40 and 60 minutes of 
incubation, lysates subjected to Western blot and probed with anti-
phosphotyrosine antibody.  Increases in the abundance of several 
phosphotyrosine-containing proteins of differing molecular weights were 
observed after stimulation with ADAMTS4 (Fig. 13F).  Robust up-regulation of a 
50kD (Fig. 13C), 115kD (Fig. 13D) and >120kD (Fig. 13E) signal was detected at 
60 minutes after addition of ADAMTS4, although the peak of the time-course was 
somewhat inconsistent among experiments.  Modest increases were seen in a 
species at ~40kD (Fig. 13A, B). 
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Figure 13. Tyrosine residue phosphorylation in total protein extract from neurons 
after treatment with human recombinant ADAMTS4.  Representative immunoblot 
showing protein bands immunoreactive with anti-phosphotyrosine antibody in 
extracts from neurons, at 5 days in culture and treated with culture medium or 50 
nM ADAMTS4 for 20, 40 and 60 min.  Proteins immunoreactive for phospho-
tyrosine were observed at several molecular weights, 42 (A), 44 (B), 50 (C), 115 
(D), >120 (E).  Protein bands from this single experiment were quantified by 
densitometry and values are shown in panel (F) indicate increases in band 
density for proteins at several different molecular weights, especially prominent is 
a band at about 40 kD.  This blot is from a representative experiment and results 
were similar in three replicate experiments. 
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Modulation of MAP kinase (ERK1/2) in response to ADAMTS4 
 The increase in the abundance of phosphotyrosine-containing proteins 
around 40 kD led us to examine the possibility that the effects on neurite 
outgrowth were mediated by ERK1/2, an intracellular factor known to have 
effects on neurite outgrowth.  Thus, neuronal extracts were examined by 
Western blot and probed with anti-"pan" ERK1/2 antibody and anti-phospho-
selective ERK1/2 antibody to determine if any changes were occurring in the 
ratio of activated (phospho) to total ERK1/2 protein in response to ADAMTS4.  
Marked increases in activated 42/44kD ERK1/2 were detected after ADAMTS4 
treatment (Fig. 14A-D), but there was some variability in the time of maximum 
stimulation.  However, elevations in the phospho-ERK1/2 / total ERK1/2 ratio 
were observed in four separate independent experiments.   
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Figure 14. ERK1/2 is activated in neurons in response to treatment with human 
recombinant ADAMTS4. 
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Figure 14. ERK1/2 is activated in neurons in response to treatment with human 
recombinant ADAMTS4.  Representative blots (A and B) and densitometric 
values of immunoreactive bands (C and D) of ERK1/2 immunoreactivity in 
extracts from neurons at 5 days in culture and treated with ADAMTS4.  Culture 
medium vehicle or human recombinant ADAMTS4 at 50 nM was added to 
neuronal culture medium and cell lysates were collected 20, 40 and 60 minutes 
after treatment, the lysates subjected to SDS-PAGE and Western blotting using 
anti-42/44kD phospho-ERK1/2 (A) and anti-pan-ERK1/2 (B) antibodies.  
Densitometry of the immunoreactivity bands was quantified and the ratio of 
phospho-ERK1/2 to pan-ERK1/2 was calculated for each sample and for each 
isoform of ERK 1/2.  (C) ratio of 42 kD activated phospho-ERK to pan- 42 kD 
ERK, (D), ratio of 44 kD activated phospho-ERK to pan- 44 kD ERK.  Marked 
and apparently sustained increases in activated ERK1/2 were observed in 
response to treatment with ADAMTS4   This experiment was repeated four times, 
with increases seen in each experiment, however, the time of the peak 
magnitude of the increase was variable among experiments,  Thus, results from 
a single, representative experiment is shown. 
 
Neurite outgrowth in the presence of MEK inhibitors 
 To determine whether the MAP kinase pathway(s) was mediating the 
neurite growth promoting effects of ADAMTS4, neurite outgrowth was quantified 
in cultures treated with selective MAP kinase inhibitors or their inactive analogs 
(Fig.15).  The MAP kinase inhibitor PD98059 (Fig. 15A) was added at 10 and 
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25µM, and neurons were treated with U0126, a potent inhibitor of MEK-1 and -2, 
at 10, 25 and 50µM (Fig. 15B).  Neurons were treated with the inactive analog of 
U0126, U0124 as a control.  The inhibitors were used alone or thirty minutes 
before the addition of 50nM ADAMTS4, and the neurons were fixed, 
immunostained and photographed.  Neurite outgrowth was quantified by the 
same procedure as the protein treatment experiments.  All neurites were traced 
in a particular field, area occupied by the tracing was determined and expressed 
as area occupied by neurite tracings divided by the number of neurons in the 
field to yield µm2 neurite tracing/neuron.  ADAMTS4 at 50 nM was effective in 
enhancing neurite outgrowth (Fig. 15A-C).  PD98059 treatment alone did not 
significantly alter neurite outgrowth in the absence of ADAMTS4, and was 
comparable to control levels at 10 and 25µM (Fig. 15A).  However, when added 
to cultures stimulated with ADAMTS4, PD98059 completely inhibited the neurite 
outgrowth promoting effects of ADAMTS4 (Fig. 15A).  When the MEK-1,-2 
inhibitor, U0126 was incubated with neurons in the presence of ADAMTS4, it 
also inhibited neurite outgrowth induced by the protease (Fig. 15B), yet at the 
highest dose tested, the drug appeared to be neurotoxic (not shown).  The 
inactive analog of U0126, U0124, did not influence ADAMTS4 induced neurite 
outgrowth at 25 and 50 µM (Fig. 15C).  At the concentrations for these 
experiments, the diluent used for each drug, DMSO, alone did not affect neurite 
outgrowth (data not shown).  These results suggest an involvement of the MAP 
kinase signaling pathway in ADAMTS4-stimulated neurite outgrowth.   
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Figure 15. MAP kinase inhibitors attenuate neurite outgrowth induced by human 
recombinant ADAMTS4 treatment 
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Figure 15. MAP kinase inhibitors attenuate neurite outgrowth induced by human 
recombinant ADAMTS4 treatment.  PD98059, an inhibitor of MAP kinase (A) 
U0126, a potent inhibitor of MEK-1 and -2 (B) and U0124, an inactive analog of 
U0126 (C) were added to the culture medium of neurons at 2 and 5 days in 
culture to determine whether inhibition of the MAP kinase could influence the 
growth of neurites induced by ADAMTS4.  Cells were treated with vehicle 
(DMSO) or inhibitor alone or with inhibitor thirty minutes before the addition of 
50nM ADAMTS4, followed by fixation, immunostaining and quantification of 
neurite outgrowth by tracing neurites on day 6 of the culture.  Area occupied by 
neurites (µm2) from neurite tracings was divided by number of neurons in the 
field to generate a mean ± SEM (µm2/neuron).  Each MAP kinase inhibitor 
significantly and dose-dependently impaired the neurite outgrowth promoting 
effects of ADAMTS4 with little effect on basal neurite outgrowth with the 
exception of high doses of U0126 which appeared to be toxic toward the 
neurons.  * signifies p ≤ 0.05 compared to "control" treatment; ** signifies p ≤ 
0.05 compared to treatment with 50 nM ADAMTS4 alone.  This experiment was 
performed using an independent culture and at least 10 fields were examined for 
each treatment group representing about 75 neurons per treatment group.  
Similar data was obtained when the experiment was repeated. 
 
Discussion 
Several rather recent studies have provided the most direct evidence to 
date for the involvement of matrix-degrading metalloproteinases in neural 
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plasticity in the CNS.  Most of these experiments were conducted in vivo and 
demonstrated increased expression of matrix-cleaving proteinases during 
conditions of regeneration and/or neuronal sprouting (Szklarczyk et al., 2002; 
Yuan et al., 2002; Mayer et al., 2005) or synaptogenesis (Kim et al., 2005) and 
that blockade of metalloproteinase activity during a critical period may impede 
neural plasticity mechanisms (Reeves et al., 2003).  In at least two of these 
studies, a PG crucial to the plastic response was identified and shown to be an in 
vivo substrate for an active metalloproteinase (Yuan et al., 2002; Mayer et al., 
2005).  Data from in vitro studies has been limited to peripheral neurons and has 
shown that metalloproteinases enhance penetration of neurites into the basal 
lamina (Nordstrom et al., 1995) and potentiate nerve growth factor-induced 
neurite extension in PC12 cells (Shubayev and Myers, 2004).  In addition in 
peripheral nerve, metalloproteinase cleavage of a PG converted the growth 
environment from an inhibitory to a permissive one, allowing for elongation of 
dorsal root ganglion neurons (Zuo et al., 1998).  In the present study, ADAMTSs 
were examined for their ability to induce neurite outgrowth in vitro in the absence 
of any other classical growth factors. The ADAMTSs used in this study are 
proteases particularly adept at cleaving aggregating, CS-containing PGs that are 
abundantly expressed in the CNS.   
Transfection of ADAMTS4 cDNA into primary rat neurons resulted in 
enhanced neurite growth compared to neurons transfected with vector alone, 
when neurons were grown on an astrocyte monolayer.  The initial interpretation 
was that elevated ADAMTS4 expression resulted in increased cleavage and/or 
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degradation of CS-containing PGs present in the astrocyte monolayer (Hamel et 
al., 2005).  Thus, the matrix was more permissive toward neurite outgrowth after 
being released from the inhibitory effects of the PGs (Zuo et al., 1998).  However, 
when neurons were cultured directly on a poly-L-lysine/laminin substrate without 
an astrocyte monolayer, the results were the same, ie. ADAMTS4 transfected 
neurons showed greater neurite outgrowth compared to vector transfected 
neurons.  This was puzzling since the abundance of matrix proteins produced in 
neuronal cultures is markedly lower than that found on astrocyte monolayers.  To 
more fully characterize whether proteolytic activity was an essential component 
in the action of the ADAMTSs in promoting neurite growth, neurons were 
transfected with a construct encoding an inactive point mutant of ADAMTS4.  
This construct contains a point mutation in the catalytic domain of ADAMTS4 
resulting in an inactive protease, yet all other domains are identical to the wild-
type protein (Gao et al., 2002).  Neurons transfected with the mutant construct 
were at least as effective as the construct encoding the wild-type, active 
protease, indicating that proteolytic activity was not required for ADAMTS4 to 
stimulate neurite extension.  It also suggests that ADAMTS4 may be acting by 
engagement with a cell surface protein, as mounting evidence indicates that 
certain biological actions are stimulated by metalloproteinase binding to cell 
surface signaling molecules, especially integrins (Conant, 2005), independent of 
proteolytic function.  Regarding the ADAMTSs, these proteinases avidly bind to 
heparan and may be anchored to the cell surface or the ECM via its 
thrombospondin motif and/or spacer region (Kuno and Matsushima, 1998; Kuno 
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et al., 1999).  ADAMTSs bind to heparan sulfate or CS chains found typically 
attached to core protein PGs, and this protein-glycosaminoglycan interaction is 
important for substrate recognition (Tortorella et al., 2000; Flannery et al., 2002; 
Kashiwagi et al., 2004).  Most recently, indirect evidence suggests that 
ADAMTS4 may bind to the cell surface heparan sulfate PG, syndecan-1, in 
chondrocyte-like cells in culture (Gao et al., 2004a) and orient the protease for C-
terminal truncation by another cell surface metalloproteinase.  Whether binding of 
syndecan-1 by ADAMTS4 directly activates intracellular signaling mechanisms is 
not known. 
Compelling evidence presented here indicates that one intracellular 
signaling mechanism induced by ADAMTS4, presumably by interacting with a 
cell surface protein, is the MAP kinase cascade.  ADAMTS-induced neurite 
extension is completely dependent on activation of this pathway since 
pharmacological inhibition of ERK1/2 kinase activity reversed the effect.  Data 
from previous investigations convincingly point to a crucial role for MAP kinase in 
process outgrowth from a variety of neuronal-like cell types.  Neurite outgrowth 
on the adhesion protein L1 in B35 neuroblastoma cells requires MAP kinase 
activation (Schmid et al., 2000) and expression of Eph8 stimulates MAP kinase 
and neurite outgrowth in NG108-15 cells (Gu et al., 2005).  Neuregulin-1 
activation of erbB receptors activates MAP kinase and stimulates hippocampal 
neuronal differentiation and neurite extension and arborization (Gerecke et al., 
2004).  These data clearly support the concept that MAP kinase activation is 
involved in, or is at least associated with, neurite extension. 
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Additional data indicates that heparan sulfate-containing proteins 
transduce signals resulting in the activation of MAP kinase.  Basic fibroblast 
growth factor (FGF)-2 binds heparan sulfate on the PG, agrin, to activate the 
ERK1/2 signal and modulate neurite outgrowth in PC-12 cells and retinal neurons 
(Kim et al., 2003).  It may be that ADAMTS mobilizes and activates bFGF by 
interacting with a heparan sulfate-containing PG, such as agrin, at the surface of 
cortical neurons, although agrin expression is much lower on CNS neurons 
compared to those from the periphery.  As mentioned above, another possible 
ADAMTS binding partner is syndecan.  Connective tissue growth factor, (CCN-
2), a protein that like ADAMTS4, contains a thrombospondin type-1 motif, is 
known to bind syndecan-2 and activate ERK1/2 (Gao et al., 2004b).  It is 
plausible that the ADAMTSs bind syndecan and activate the MAP kinase 
cascade, thereby increasing neurite extension.  We have demonstrated that 
ADAMTSs induce MAP kinase signaling in primary rat cortical neurons, an action 
essential for ADAMTS-induced neurite outgrowth.  Compared to neuron-like cell 
lines which are the cells typically used to demonstrate signaling by the MMPs, 
the primary cultured neurons from embryonic rat cortex used in these studies are 
a model that more closely parallel neurons in vivo in their receptor and signaling 
ensemble. 
One primary candidate, functional motif in the structure of ADAMTS4 that 
may be responsible for enhancing neurite elongation is the type-1 
thrombospondin motif.  Thrombospondin itself enhances neurite outgrowth 
(O'Shea et al., 1991) and the thrombospondin type-1 repeats of SCO-spondin 
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bind to α1β1 integrin to stimulate cell process extension in B104 cells, a neuron-
like cell line (Bamdad et al., 2004).  Furthermore, other ECM proteins that contain 
thrombospondin-like motifs, such as heparin-binding growth-associated molecule 
(HB-GAM, also known as pleiotrophin) and midkine, increase neurite outgrowth 
in hippocampal neurons (Raulo et al., 2005).  Thus, there is strong evidence that 
thrombospondin-like regions of various proteins expressed in and secreted by 
neurons (or astrocytes via a paracrine action) may affect neural plasticity.   
In sum, these results indicate that the ADAMTSs, similar to the MMPs 
(Conant, 2005), exert biological activities independent of their proteolytic activity, 
one of them that induces extension of neurites in primary cultured embryonic 
neurons.  The particular motif on the ADAMTSs responsible for stimulating this 
effect is not known, but evidence from others points to the thrombospondin type 
1 repeat or the spacer region.  Since this carboxy-terminal may bind to heparan 
sulfate chains, the cell surface molecules that bind the ADAMTSs likely differ 
markedly from the MMPs, molecules that do not contain a thrombospondin 
repeat.  Preliminary, unpublished data from our laboratory indicates that the 
ADAMTSs stimulate neurite outgrowth on a CS-containing substrate that is laid 
on plastic in vitro.  It will be interesting to determine whether this activation of 
neurite extension is dependent on or independent of ADAMTS proteolytic activity. 
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Chapter 3: ADAMTS4 (A Disintegrin and Metalloproteinase with Thrombospondin 
Motifs 4) Inhibits Maturation of Dendritic Spines in Neurons in vitro 
 
Abstract 
 Dendritic spines are tiny protuberances that extend from the dendritic 
shaft which are the sites for the majority of excitatory neurotransmission in the 
central nervous system (CNS).  Alterations in dendritic spine morphology are 
now recognized as a reliable indicator of changes in synaptic function.  The 
components of the extracellular matrix (ECM) may mediate plasticity in the CNS 
and the most abundant family of proteins which make up the ECM, the lectican 
family of chondroitin sulfate (CS)-containing proteoglycans (PG), play important 
roles in cell adhesion, migration and inhibition of neurite outgrowth.  Little is 
known about whether lecticans modulate synaptic plasticity, although indirect 
evidence indicates that they may do so.  Proteases that cleave and degrade 
various components of the ECM are increasingly recognized as significant 
contributors to the functional state of the ECM, and proteolysis of lecticans may 
affect plasticity.  Increased proteolysis of lecticans by members of the ADAMTS 
family of proteases, enzymes well known to cleave lecticans, may change 
synaptic morphology and plasticity in neurons in vitro.  To test this hypothesis, 
neurons were cultured and increased levels of ADAMTS4 were introduced by 
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direct treatment with recombinant protein or by transfection of neurons with a 
DNA expression vector to drive the expression of ADAMTS4.  Various 
measurements of dendritic spine morphology were made several time points 
after addition.  Furthermore, levels of synaptic markers which correlate with 
synaptic abundance were quantified by ELISA and immunostaining.  After 
ADAMTS4 treatment, several alterations were detected in dendritic spine 
morphology, including increased overall length of spines and an increased 
percent of protrusions that were defined as filopodia.  A concurrent decrease in 
PSD-95 staining was detected on the neurites of young neurons overexpressing 
ADAMTS4 or expressing proteolytically-inactive mutant ADAMTS4 protein.  
Thus, ADAMTS4 may promote plasticity in neurons in vitro by inhibiting the 
formation, maturation and/or stabilization of synapses. 
 
Introduction 
The significance of alterations in synaptic structure has been 
acknowledged for its correlation with functional changes in the brain.  One such 
structural modality in the brain is the dendritic spine, which is a small protrusion 
that extends from the dendritic shaft and most often contains a single synapse 
representing the site for the majority of excitatory neurotransmission in the CNS 
(Yuste and Bonhoeffer, 2001).  Dendritic spines were identified in the 19th 
century by Ramon y Cajal and sometimes are formed as long, thin protrusions 
known as filopodia which may mature into shorter spines of varying shapes (Ziv 
and Smith, 1996; Fiala et al., 1998; Harris, 1999), although a spine can 
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circumvent filopodial morphology and appear as a spine outright (Engert and 
Bonhoeffer, 1999; Marrs et al., 2001).  In cultured neurons, spines are more 
numerous in mature neurons while filopodia are more abundant in young 
neurons (Dailey and Smith, 1996).  Filopodia are highly motile and spines 
themselves are dynamic structures (Dunaevsky et al., 1999; Parnass et al., 2000; 
Bonhoeffer and Yuste, 2002), and this motility has been observed with two-
photon laser scanning microscopy (Grutzendler et al., 2002; Majewska et al., 
2006; Yasuda et al., 2006).  Interestingly, changes in spine morphology and 
density result from the induction of long term potentiation (LTP) and enhanced 
neuronal activity.  Furthermore, abnormal morphology of dendritic spines is 
associated with a host of cognitive disorders that includes autism, mental 
retardation and even disorders that involve neurodegeneration such as animal 
models of Alzheimer’s disease (Hering and Sheng, 2001; Yuste and Bonhoeffer, 
2001; Nimchinsky et al., 2002).   
PGs of the ECM are emerging as important extracellular modulators of 
neural plasticity, and although most evidence that points to this role is indirect 
and descriptive, it encourages further research into the ability of PGs to regulate 
synaptic maturation and function.  PGs of the lectican family, brevican, neurocan, 
versican and aggrecan contain CS side chains, and their developmental 
expression is coincident with the maturation and stabilization of synapses within 
the CNS (Yamaguchi, 2000).  Furthermore, brevican levels remain high in the 
adult and throughout the life of the animal, suggesting these PGs may play a role 
in the development of synaptic stabilization (Milev et al., 1998).  In addition to 
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temporal evidence, localization studies demonstrate a role for brevican in 
synaptic stabilization.  Brevican is deposited around but not over the synapse, 
effectively “walling-off” the synapse in an envelope of ECM, and it is thought that 
the presence of this lectican reinforces the strength of the synapse (Yamaguchi, 
2000).  Knock-out studies have not shown a clear necessity for lecticans in 
synaptic stabilization, however, further studies are needed in these experiments 
to guard against making generalizations without knowing whether compensatory 
increases in the expression of other lecticans may account for the lack of 
phenotype (Zhou et al., 2001; Brakebusch et al., 2002; Rauch et al., 2005).  At 
any rate, brevican knockout mice display impaired LTP, which interestingly is an 
effect that may be replicated by infusion of anti-brevican antibody in the brain 
(Brakebusch et al., 2002). 
ADAMTSs, a family of glutamyl endopeptidases, cleave PGs, and it has 
been proposed that proteolytic alterations in matrix components can lead to 
plastic changes, however it is unknown whether any effects seen by the 
ADAMTSs are due to proteolysis of PGs or by a signaling component in their 
own right as we have shown for neurite outgrowth.  Several studies indicate a 
role for ADAMTSs in response to injury or inflammation.  Treatment of rat 
neurons in culture with amyloid ß results in increased levels of ADAMTS4 
transcript (Satoh et al., 2000).  Kainate-induced excitotoxic lesion induced an 
upsurge of mRNA for ADAMTS1 and 4 with a concurrent increase in the 
proteolytic fragment of brevican produced by ADAMTS cleavage (Yuan et al., 
2002).  Additionally, ADAMTS1 was increased in the spinal cord of rats that 
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underwent axotomy (Sasaki et al., 2001).  ADAMTS1, but not ADAMTS5 is 
increased in Down Syndrome, Pick’s Disease and Alzheimer’s Disease (Miguel 
et al., 2005).  Again, it was not certain whether these changes were due to 
proteolysis or signaling events induced by ADAMTSs, since our lab has 
previously shown that ADAMTS4 activates the mitogen-activated protein kinase 
(MAPK) pathway to increase neurite length (Hamel et al., 2005).  Proteases 
belonging to a related family, the matrix metalloproteinases (MMP), have been 
shown to induce signaling in cells in the absence of proteolytic action. 
 This study seeks to elucidate whether ADAMTSs modulate synaptic 
contacts, as measured by changes in dendritic spine morphology and 
quantification of immunoreactivity for key synaptic markers related to synaptic 
abundance using ELISA and immunostaining.  Two presynaptic markers, 
synaptophysin and synaptosomal-associated protein of 25kD (SNAP-25) and one 
post-synaptic marker (localized to the scaffolding of dendritic spines), post-
synaptic density-95 (PSD-95), will be quantified.  Here we show that in cultured 
neurons, spine lengths were increased as were the proportion of immature 
filopodia in response to treatment with ADAMTS4 recombinant protein.  
Furthermore, decreases in the levels of PSD-95, a postsynaptic marker highly 
enriched in the post-synaptic scaffolding, were detected were detected in 
response to increased expression of ADAMTS4 or expression of proteolytically-
inactive mutant ADAMTS4.  Our findings appear to identify a role for ADAMTS4 
in modifying synaptic maturation. 
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Materials and Methods 
Primary neuronal culture 
Primary cultures of neurons were prepared from cerebral cortex of 
embryonic day 18 Sprague Dawley (Harlan, Indianapolis) rat pups in Dulbecco's 
Modified Eagles Medium containing 10% horse serum as described previously 
(Hamel et al., 2005).  After isolation, neurons were plated directly on substrate-
coated glass coverslips or subjected to transfection by electroporation before 
plating on the same coverslips.  After twenty-four hours, culture medium was 
exchanged for serum-free neuronal growth medium (Neurobasal medium 
(Invitrogen) containing B-27 defined supplement (Invitrogen), 0.5mM Glutamax II 
(Gibco, Carlsbad), 25µM glutamate and 1% antibiotic/antimycotic solution 
(Gibco)) for the duration of the culture. 
 
Transfection by electroporation 
DNA expression constructs of ADAMTS4 were made for transfection of 
primary rat cells from forebrain of embryonic day 18 rat pups.  A cDNA for 
ADAMTS4 (Gao et al., 2002), and an inactive point mutant of ADAMTS4 362 
(E→Q) (Gao et al., 2004a) that were inserted into pcDNA (Invitrogen), were 
restricted with Xba I and Kpn I (Promega, Madison), the ADAMTS4 (or mutant) 
fragment purified from an agarose gel and ligated into linearized pCMS plasmid, 
a dual promoter vector that expresses enhanced green fluorescent protein 
(EGFP) driven by SV40 (Clontech, Mountain View, CA), and the inserted gene 
driven by the cytomegalovirus promoter.  After cells from cerebral cortex of E18 
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SD pups were isolated, 5x106 cells were centrifuged and resuspended in 100µl 
rat nucleofector solution (Amaxa Biosystems, Gaithersburg, MD).  The cells were 
transferred to a cuvette and pCMS, pCMS-ADAMTS4 or pCMS-ADAMTS4 
mutant were added and the cuvette subjected to electric current using the 
Nucleofector electroporator (Amaxa Biosystems) with either the O-03 or G-13 
time and current pre-programmed by the manufacturer.  Immediately after 
transfection, 500µl of pre-warmed, 37°C Dulbecco's Modified Eagles Medium 
with 10% fetal calf serum was added to the cell suspension, and the cells were 
transferred to a sterile microcentrifuge tube until plating.  The transfected 
neurons were plated on glass coverslips pre-coated with the laminin/poly-L-lysine 
substrate.  Neurons were allowed to grow for 8-11 DIV or 20-22 DIV.  After this 
time, cells were washed one time in PBS, fixed in 4% room temperature 
paraformaldehyde for twenty minutes, and washed an additional three times with 
PBS, followed by immunocytochemistry to stain the synaptic proteins, 
synaptophysin, SNAP-25 and PSD-95.   
 
Immunocytochemistry 
Neuronal cultures fixed as described above were incubated for one hour in 
blocking buffer containing 10% normal goat serum (NGS), 0.3% triton-X-100 and 
1M lysine in PBS at room temperature.  Cells were incubated for 2 hours at room 
temperature in dilution buffer (PBS, 10% NGS, 0.3%Triton-X-100) containing 
rabbit anti-synaptophysin (Dako, Carpinteria, CA) diluted to 1:200, rabbit anti-
SNAP-25 (Sigma, St. Louis, MO) diluted to 1:200 or mouse anti-PSD-95 
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(Chemicon, Temecula, CA).  The cells were washed three times in PBS and 
Alexa Fluor 588 goat anti-mouse (or goat anti-rabbit) IgG fluorescent secondary 
antibody (Invitrogen, Carlsbad, CA) was incubated at a concentration of 1:500 for 
1 h and the coverslips washed three times in PBS.  The coverslips were then 
mounted on slides with Vectashield (Vector Laboratories, Burlingame, CA) 
fluorescent mounting medium and the cells were visualized with epifluorescence.   
 
Quantification of synaptic marker immunostaining 
Levels of immunoreactivity of synaptic proteins expressed by transfected 
cells were quantified.  Transfected and immunostained cells were visualized 
under epifluorescence using a Zeiss Axioskop microscope interfaced with an 
Axiocam (Zeiss, Thornwood, NY) digital camera and captured with uniform 
exposure time with Openlab software (version 3.1.4, Improvision, Lexington, 
MA).  Transfected cells were visualized using the FITC filter, and once a transfect 
was located, the rhodamine filter was then employed to capture an image of the 
red synaptic marker staining on the transfected cell.  Images were analyzed 
using NIH ImageJ version 1.35S (NIH, Bethesda, MD).  To quantify optical 
density of the immunostain on the soma, the maximum optical density of 
immunostain contained within a 50µm2 square on the neuronal cell body was 
quantified by NIH ImageJ.  For quantification along a neurite, a 20µm segment 
was analyzed.  This analysis was performed with young (8-11 DIV) and mature 
(20-22 DIV) neurons.  Quantification was performed with the treatment unknown 
to the experimenter using 570 neurons from 2 cultures, and data were 
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statistically assessed by ANOVA followed by Newman-Keuls multiple comparison 
post-test.  p<0.05 was considered a significant difference between groups.  
 
ADAMTS4 protein treatment 
For dendritic spine experiments, 2.5x105 neurons were cultured on 22 mm 
glass coverslips, and for protein extraction experiments, 3.625x106 neurons were 
cultured on 100mm tissue culture dishes for 8-11 DIV (young) or 20-22 DIV 
(mature).  Purified recombinant ADAMTS4, provided by Roche Biosciences, was 
diluted in Neurobasal medium plus 0.1% bovine serum albumin (BSA) and 
syringe filtered to sterilize.  BSA was added to prevent adherence of the 
recombinant protein to the filter.  Each of the ADAMTS protein preparations 
contained low, but detectable levels of endotoxin using the LAL assay (Cambrex, 
Walkersville, MD) that were comparable to the BSA controls.  Filtered 50nM 
ADAMTS4 was applied to the culture and the cells were incubated for 2-3 days.  
Control wells received a matched volume of filtered Neurobasal medium plus 1% 
BSA.  After the incubation was complete, the neurons were processed for ELISA 
or dendritic spine examination. 
 
Dendritic spine analysis 
Neurons treated with 50nM ADAMTS4 human recombinant protein were 
used for the examination of dendritic spines.  After protein treatment, neurons 
were fixed in 4% paraformaldehyde as described above followed by incubation 
with a fluorescent-tagged, actin binding protein, Alexa-Fluor 488 phalloidin 
 86
(Molecular Probes/Invitrogen), at a dilution of 1:500 in 2% NGS and 0.3%Triton-
X-100 in PBS for 20 minutes at room temperature, followed by an additional 
three rinses in PBS.  Neurons were imaged using a Leica TCS SP2 confocal 
scanning laser microscope with a 63X objective (numerical aperture, 1.4) with a 
zoom of 2 and z-sectioned in increments of 0.3µm.  2D maximum reconstructions 
were generated from the z-stacks and utilized for quantification of spines.  NIH 
ImageJ was used to perform several measurements of the dendritic spine (Harris 
et al 1992, Koh et al, 2002).  The length of the spine was measured from the 
dendrite to the tip of the spine; maximum spine head diameter and the minimum 
neck diameter were measured as well.  The ratio of the measurements of 
maximum head diameter to the minimum neck diameter were used to place 
spines into categories of filopodial, stubby, mushroom and thin (Zagrebelsky M et 
al, 2005;Peters & Kaisrman-Abramof, 1969; Nakayama AY et al, 2000).  Any 
protrusion >3µm in length was considered a filopodia.  A spine with a length 
≤3µm with a ratio of head to neck≥1.5 was considered a mushroom spine.  Thin 
spines had a head/neck ratio <1.5 with 1≥ Length ≤3.  Stubby spines had a 
head/neck ratio <1.5 with Length ≤1.  All measurements were performed blindly 
with the experimental group being quantified unknown to the personnel.  
Statistical significance was assessed by unpaired t-test, and a p<0.02 was 
considered significant. 
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ELISA 
 After control or 50nM ADAMTS4 treatment, RIPA buffer (50mM Tris, 
150mM NaCl, 1mM EDTA, 1mM EGTA, 1% triton-X-100, 1% sodium 
deoxycholate, 0.1% SDS) with protease inhibitor cocktail (set III, Calbiochem, 
San Diego) was added to the culture on ice to extract protein, followed by 
analysis by ELISA to determine the levels of synaptic markers.  ELISAs were 
conducted to measure immunoreactivity of synaptophysin, SNAP-25 and PSD-95 
were performed.  Briefly, coating antibody in buffer (0.01M phosphate buffer) was 
applied to the EIA/RIA high-binding 96-well plates (Costar) with: mouse anti-
synaptophysin (Chemicon) at a dilution of 1:250, mouse anti-SNAP-25 
(Chemicon) at a dilution of 1:200 or mouse anti-PSD-95 (Chemicon) at a dilution 
of 1:100.  The plates were agitated overnight and the antibody was allowed to 
adhere to dryness at room temperature.  The wells were then washed with 
sample/wash buffer (PBS with .05% Tween-20) one time.  Blocking buffer (PBS 
with 0.05% Tween-20 and 5% dry milk) was applied to the wells and incubated at 
room temperature for 1 hour with agitation, followed by washing and applying cell 
extract diluted in sample/wash buffer for two hours at room temperature with 
agitation.  Sample was then washed from the well followed by the addition of 
primary antibody for two hours in buffer: rabbit anti-synaptophysin (Dako) at a 
dilution of 1:2000, rabbit anti-SNAP-25 (Sigma) at a dilution of 1:1000 and sheep 
anti-PSD-95 (Zymed) at a dilution of 1:100.  The wells were washed three times 
and secondary antibody applied in buffer for one hour: (goat anti-rabbit IgG-HRP 
(Chemicon) at 1:5000 or anti-sheep/goat (Chemicon) at a dilution of 1:1000).  
 88
Blue reaction product was detected after the application of TMB (Sigma) and 
reaction stopped with 1M H2SO4.  Absorbance levels were detected with a 
Wallac Victor2 1420 multilabel counter (Perkin Elmer, Wellesley, MA) interfaced 
with Workout software (version 1.5, Perkin Elmer), and these levels were 
normalized per µg protein applied to the well.  The time course of synaptophysin 
and PSD-95 levels in untreated, control neurons was performed with cell extracts 
from three neuronal cultures and means from experimental groups compared 
using ANOVA and pair-wise comparisons were made with Newman-Keuls post-
hoc test (GraphPad, San Diego, CA).  A p<0.05 was considered a significant 
difference between groups. 
 
Results 
Analysis of spine density and length 
 Changes in the morphology of dendritic spines are routinely used as 
measures of synaptic maturation, and to determine whether ADAMTS4 could 
affect dendritic spine morphology, neurons were subjected to ADAMTS4 or 
vehicle treatment, fixed in 4% paraformaldehyde and spines detected with the 
fluorescent-tagged actin-binding protein, phalloidin (Fig. 16 A, B).  Spine length, 
maximum head diameter and minimum neck diameter were quantified using NIH 
ImageJ, and these measurements were used in several analyses.  The mean 
density of spines was calculated by averaging the number of spines measured 
per 10µm segment of dendrite analyzed for control and ADAMTS4-treated young 
and mature neurons (Fig. 16 C), and no alterations in spine density was detected 
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with treatment with ADAMTS4 in either young or mature neurons.  Since longer 
protrusions often indicate less mature spines, mean spine length was calculated 
by averaging the lengths for each protrusion measured (Fig. 16, D), and 
ADAMTS4 treatment significantly increased the lengths of protrusions (spines 
and filopodia included) in young and mature neurons. 
 
Figure 16. Human recombinant ADAMTS4 increases dendritic protrusion length 
in young and mature neurons. 
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Figure 16. Human recombinant ADAMTS4 increases dendritic protrusion length 
in young and mature neurons.  Photomicrographs of primary rat cortical neurons 
treated with culture medium containing BSA (A) or 50nM ADAMTS4 (B) are 
depicted and quantifications of protrusion density (C) and protrusion length (D) 
are shown, which were examined at 8-11 DIV (Young) or 20-22 DIV (Mature).  At 
the end of culture, dendritic spines were visualized by using the Alexafluor 488-
conjugated actin binding protein, phalloidin.  Spines were analyzed with NIH 
ImageJ, and mean protrusion density was calculated by averaging the number of 
protrusions (spines and filopodia) per 10µm segment of dendrite measured (C), 
and mean spine length was calculated by averaging lengths for all protrusions  
measured (D).  Treatment with ADAMTS4 did not significantly alter spine density 
(C), however, spine length was significantly increased (D) in young and mature 
neurons with ADAMTS4 treatment.  (* p ≤ 0.02 compared to young control, ** p ≤ 
0.02 compared to mature control).  Three separate cultures were utilized in these 
experiments.  n=133, young control; 167 young ADAMTS4; 211, mature control; 
115, mature ADAMTS4, C.  n=763, young control; 977 young ADAMTS4; 1289, 
mature control; 750, mature ADAMTS4, D. 
 
Analysis of dendritic spine morphology 
Since changes in spine morphology can reflect changes in synaptic 
function, spines were categorized into morphological classes utilizing the 
measurements detailed above to determine whether ADAMTS4 could alter the 
proportion of spine types.  The morphology of spines is used as an indicator of 
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their maturity, with filopodia defined as precursors to spines, thin spines being 
the most immature spines followed by mushroom spines being more mature and 
stubby spines the most mature.  The percentages of different spine types was 
calculated by averaging the numbers of different types divided by the total 
number of spines measured for each 10µm segment of dendrite measured.  In 
accordance with the previous finding of ADAMTS4 increasing length, ADAMTS4 
treatment increased the percentage of filopodia, the longest in length of the 
morphological categories in both young and mature neurons (Fig. 17, top left 
panel).  ADAMTS4 treatment also significantly increased the percentage of thin 
spines while decreasing the percentage of stubby spines in mature neurons (Fig. 
17, top right and bottom right panels). 
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Figure 17. Treatment of primary neurons with ADAMTS4 alters the proportion of 
various spine types. 
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Figure 17. Treatment of primary neurons with ADAMTS4 alters the proportion of 
various spine types.  Percentages of filopodia, thin spines, mushroom spines and 
stubby spines are depicted in neurons treated with culture medium containing 
BSA (control) or 50nM ADAMTS4 examined at 8-11 DIV (Young) or 20-22 DIV 
(Mature).  At the end of the treatment period, dendritic spines were visualized by 
using the Alexafluor 488-conjugated actin binding protein, phalloidin.  Spines 
were analyzed with NIH ImageJ, and mean percentage of type was calculated by 
averaging the percentage of protrusion calculated for each 10µm segment 
measured.  Treatment with ADAMTS4 significantly increased the percentages of 
filopodia in young and mature neurons (upper left panel), and significantly 
increased the percentage of thin spines while reducing the percentage of stubby 
spines in mature neurons (upper and lower right panels).  (* p ≤ 0.02 compared 
to young control, ** p ≤ 0.02 compared to mature control). Three separate 
cultures were utilized in these experiments.  n=133, young control; 167 young 
ADAMTS4; 211, mature control; 115, mature ADAMTS4. 
 
Quantification of localized synaptic proteins 
Since changes were detected in the morphology of spines, we were next 
interested in determining whether there would be concurrent alterations in 
proteins enriched at the synapse, but before directly examining ADAMTS4 
treated neurons, a time course detecting synaptic proteins was conducted in 
control-treated neurons to verify that these ELISAs could detect maturational 
changes in the expression of these synaptic proteins.  Neurons were grown and 
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cell proteins extracted at 5, 12 and 21 DIV.  Synaptophysin levels increased in 
control neurons as the culture aged (Fig. 18, upper panel).  PSD-95 protein 
levels showed a similar increase in individual cultures, however, due to variability 
between these values, these increases were not statistically significant (Fig. 18, 
lower panel). 
 
Figure 18. Synaptic marker proteins increase with neuronal culture age. 
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Figure 18. Synaptic marker proteins increase with neuronal culture age.  Units of 
synaptophysin (upper panel) and PSD-95 (lower panel) immunoreactivity per µg 
protein measured by ELISA in neurons at 5, 12 and 21 DIV.  Neurons were 
grown under basal conditions, proteins extracted at days 5, 12 and 21 and 
subjected to synaptophysin or PSD-95 ELISA.  Units of immunoreactivity were 
normalized per µg protein, and significant increases in immunoreactivity are 
detected in synaptophysin (upper panel), but not PSD-95 (lower panel) as DIV 
increases.  *, significant difference from 5DIV, p<0.05, **, significant difference 
from 12 DIV, p<0.05.  This experiment was performed three times using cells 
isolated from separate litters of rat pups. 
 
To determine whether ADAMTS4 treatment could lead to alterations in 
synaptic protein levels, neurons were treated with ADAMTS4 or vehicle culture 
medium containing BSA, the treatment continued for 2 days and cell proteins 
extracted at 8-11 DIV (Young) or 20-22 DIV (Mature).  Despite seeing clear 
changes in dendritic spine morphology, no significant alterations in levels of 
synaptophysin (Fig. 19, upper panel), SNAP-25 (Fig. 19, middle panel) or PSD-
95 (Fig. 19, lower panel) were observed in response to ADAMTS4 treatment. 
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Figure 19. ADAMTS4 does not significantly alter synaptic protein levels. 
 
 97
Figure 19. ADAMTS4 does not significantly alter synaptic protein levels.  
Quantitative analysis of immunoreactivity of synaptophysin (upper panel), SNAP-
25 (middle panel) and PSD-95 (lower panel) in neurons treated with medium 
containing BSA (control) or 50nM ADAMTS4 in neuronal proteins extracted at 8-
11 DIV (young) or 20-22 DIV (mature)as measured by ELISA.  Treatment was 
incubated for 2-3 days followed by extraction of proteins and subjection to 
synaptophysin, SNAP-25 or PSD-95 ELISA.  Units of immunoreactivity were 
normalized per µg protein.  These experiments were performed three times 
utilizing cell cultures derived from 3 separate litters of rat pups. 
 
Alterations in immunostaining of synaptic proteins 
Since ADAMTS4 was clearly affecting dendritic spine morphology, yet no 
changes were seen in synaptic proteins as detected by ELISA, changes in 
synaptic markers were examined by immunocytochemistry to clarify the previous 
findings, and potentially find localized changes in synaptic marker expression 
that were not detected with the sensitivity of ELISA.  Instead of protein treatment, 
these neurons were transfected with a vector to drive the expression of 
ADAMTS4, mutant ADAMTS4 or empty vector (Fig. 20, A, C, E).  Neurons were 
transfected and allowed to grow for 8-11 DIV or 20-22 DIV, and following this, the 
neurons were fixed and immunostained for synaptophysin, SNAP-25 and PSD-
95 (Fig. 20, B, D, F).  Transfected neurons were visualized by their green color 
since the vector to drive the gene of interest contains a separate promoter to 
drive the expression of EGFP, and once a transfected cell was visualized, red 
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immunostaining of synaptic proteins on EGFP-expressing transfected neurons 
was quantified for staining detected on the cell bodies and neurites of transfected 
neurons.  Experimental groups were compared to empty vector alone transfects, 
and no changes were detected in immunostaining on cell bodies (Fig. 21, A-F), 
however, there was a trend toward a decrease in PSD-95 levels in the cell bodies 
of mature neurons (Fig. 21, F).  When the immunostaining of synaptic proteins 
was quantified on the neurites of transfected neurons, there was a significant 
decrease in PSD-95 staining on the neurites of young neurons overexpressing 
ADAMTS4 and expressing the ADAMTS4 mutant protein (Fig. 22, E).  
Immunostaining of adjacent neurons was also quantified with no significant 
correlations to ADAMTS transfection seen (data not shown). 
 
Figure 20. Synaptic marker staining in transfected neurons.  Neurons were 
transfected with empty vector (E), a vector to drive the expression of ADAMTS4 
(C) and a vector to drive the expression of proteolytically inactive mutant 
ADAMTS4 protein (A), allowed to grow for various time points, fixed and 
immunostained for synaptophysin (B), SNAP-25 (D) and PSD-95 (E).  Neurons 
pictured are 21 DIV.  Scale = 5µm. 
 
 
 
 
 
 99
Figure 20. Synaptic marker staining in transfected neurons. 
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Figure 21. Alterations in levels of synaptic markers on neuronal cell bodies in 
response to ADAMTS4. 
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Figure 21. Alterations in levels of synaptic markers on neuronal cell bodies in 
response to ADAMTS4.  Primary neurons transfected with a vector to drive the 
expression of ADAMTS4, an ADAMTS4 mutant construct, or controls transfected 
with empty vector, and allowed to grow to a specific young (8-11 DIV, A, C, E) or 
mature (20-22 DIV, B, D, F) time point after which the cells were fixed and 
immunostained for Synaptophysin, SNAP-25 or PSD-95.  For transfected cells, 
the maximum optical density of immunoreactivity over a 50µm2 area of the cell 
body was quantified for: Synaptophysin (A-B), SNAP-25 (C-D) or PSD-95 (E-F).  
No significant alterations in immunostaining were observed in response to 
ADAMTS4 or mutant ADAMTS4 transfection.  19≤n≥64 for each group 
quantified. 
 
Figure 22. Alterations in immunoreactivity of synaptic markers on neurites of 
transfected neurons.  Control, ADAMTS4 and mutant ADAMTS4-transfected 
neurons were grown for 8-11 DIV (A, C, E) or 20-22 DIV (B, D, F), followed by 
fixation and immunostaining for synaptic markers along a 20µm length of the 
neurites of transfected cells.  Optical density of synaptophysin (A-B), SNAP-25 
(C-D) and PSD-95 (E-F) staining was quantified, and PSD-95 staining was 
significantly reduced in ADAMTS4 and mutant ADAMTS4-transfected neurons.  
*, significant difference from PCMS, p<0.05.  20≤n≥56 for each group quantified. 
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Figure 22. Alterations in immunoreactivity of synaptic markers on neurites of 
transfected neurons. 
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Discussion 
 These studies present evidence to indicate that ADAMTS4 plays a role in 
the maturation of dendritic spines.  We show that ADAMTS4 treatment of primary 
cultured neurons increases the proportion of immature, filopodial protrusions in 
comparison to the proportion of filopodia in untreated cultures.  Additionally, we 
show that ADAMTS4 protein treatment of mature neurons converts mature 
stubby spines to filopodia.  This effect was correlated with a decrease in PSD-95 
staining, especially in the neurites of young neurons.  This effect appears to be 
independent of the proteolytic action of ADAMTS4 in that these neurons were 
cultured on poly-l-lysine/laminin substrate and in addition, transfection of a vector 
to drive the expression of an inactive mutant ADAMTS4 resulted in a loss of 
PSD-95 immunoreactivity.  Thus, the presence of increased levels of ADAMTS4 
could play a critical role in activating a plastic response in the adult CNS, or even 
the loss of synapses associated with inflammation and neurodegenerative 
disease. 
 The role of extracellular proteases in neural and synaptic plasticity is 
largely unknown, although these proteases are increasingly recognized as 
important mediators in the reorganization of the ECM that occurs during the 
plastic response after injury.  There is an absence of data examining whether the 
ADAMTSs mediate synaptogenesis in the CNS, or whether they have a role at all 
in vivo.  The mechanism by which ADAMTS4 reverses or inhibits the maturation 
of dendritic spines is currently unknown.  Our studies indicate that this effect may 
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be independent of the proteolysis since the proteolytically inactive mutant 
ADAMTS4 reduced levels of PSD-95 in a similar fashion to native ADAMTS4. 
Our laboratory has presented the first evidence to indicate that ADAMTSs 
may act by signaling at the cell surface to mediate cell functions.  Due to this 
scant substantiation that ADAMTSs can act in a role other than proteases, we 
turn to a related family of proteases, the matrix metalloproteinases (MMP), that 
demonstrate that proteases can act in a signaling capacity.  In fact, treatment of 
neural cells with MMP-1, a collagen protease, decreases levels of cAMP and 
activates a pertussis-toxin sensitive G protein-coupled receptor to stimulate the 
release of MMP-9 (Conant et al., 2002).  Furthermore, MMP-1 interacts with α2β1 
integrin to stimulate dephosphorylation of Akt and induce neuronal death (Conant 
et al., 2004).  Additionally, MMP-7 was recently shown to transform mature 
mushroom spines to immature filopodia, an effect very similar to those presented 
here by ADAMTS4, and this action was independent of proteolysis by MMP-7 
(Bilousova et al., 2006).  Thus, it is highly likely that the ADAMTSs can act as 
signaling molecules, and more than proteases. 
The mechanism of ADAMTS4 action to inhibit the maturation of dendritic 
spines is unknown.  If this effect is independent of proteolysis, there are many 
possibilities as to what the mediators may be.  Our lab previously showed that 
ADAMTS4 treatment induces activation of extracellular signal-related kinase 
(ERK) 1/2 MAPK to increase neurite outgrowth, and other studies indicate that 
phosphorylation of ERK1/2 leads to varied effects on synapses.  Brain-derived 
neurotrophic factor (BDNF) increases spine density in hippocampal CA1 
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pyramidal neuronal cultures through activation of ERK1/2 (Alonso et al., 2004).  
Furthermore, treatment of mature hippocampal neurons with semaphorin3A 
activated ERK1/2 to reduce the staining intensity of PSD-95 and synaptophysin 
(Bouzioukh et al., 2006).  Thus, ERK1/2 activation could potentially lead to 
modulations in synapses through its activation by ADAMTS4.  There are several 
other possibilities for mediators of synaptogenesis by ADAMTS4.  The ADAMTSs 
carry thrombospondin (TSP) type-1-like motifs and TSP itself is implicated in 
synaptogenesis.  TSP-1 and -2, which promote synaptogenesis in vitro as well as 
in vivo, are expressed by immature astrocytes, but not by mature astrocytes, and 
the authors suggest that this temporally regulated lack of expression by mature 
astrocytes may explain why the adult CNS is largely unable to support 
synaptogenesis (Christopherson et al., 2005). 
Yet another possibility of the mechanism of action of ADAMTS4 is through 
the actions of syndecan-2, a heparan sulfate-containing PG.  Interestingly, 
syndecan-2 induces mature dendritic spines in young neurons (Ethell and 
Yamaguchi, 1999; Ethell et al., 2001), and what’s more, ADAMTS4 clearly binds 
syndecan-1 (Gao et al., 2004).  It is unclear whether this binding could affect 
dendritic spine maturation.  It may be that syndecan-1 sequesters ADAMTS4 to 
block its effects in potentiating the immature morphology of filopodia.  Further 
studies are clearly needed to elucidate the role of this interaction in 
synaptogenesis. 
 Regardless of the mechanism of action of ADAMTS4 in synaptogenesis, 
the results presented in this study implicate ADAMTS4 as an important mediator 
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of synaptic morphology and therefore, function.  If mature spines can be 
destabilized and reversed to an immature phenotype, this could lead to new 
synaptic connections or perhaps a loss of current synapses.  Additionally, this 
effect could provide a mechanism for the loss of synapses that occurs in many 
inflammatory conditions where ADAMTS expression is increased.  At any rate, 
this study presents exciting evidence to indicate that the ADAMTSs play an 
important role in synaptogenesis that warrants further examination. 
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Conclusions 
 
 Neural plasticity is a complex phenomenon involving cell proliferation, 
migration, neurite outgrowth and synaptogenesis, and while this process is 
paramount in the development of the immature CNS, most regions of the adult 
CNS exhibit limited neural plasticity in response to experience, attrition or injury.  
Understanding how changes in the morphology and function of neurons (and the 
nervous system) are activated and regulated is critical to treating injured adult 
brains where plasticity is often inadequate for complete reinnervation and 
recovery of function.  Evidence is emerging to indicate the importance of the 
ECM, especially highly negatively charged, CS-containing, PGs, in limiting 
regeneration and remodeling responses of the CNS.  Additionally, it might be 
possible to overcome these limitations of the ECM by degrading either the CS 
polysaccharides or by proteolytic cleavage of the core PG proteins.  Our studies 
sought to determine how proteolytic degradation of the ECM regulates the neural 
plastic response, specifically neurite outgrowth and synaptogenesis.  In sum, 
these studies have shown that astrocytes and neurons cultured in vitro 
expressed the PG, brevican, and in astrocytes, the amount of secreted, intact 
brevican holoprotein was increased by treatment with TGFß, at least in part via 
down regulation of ADAMTS activity.  Additionally, we found that astrocytes, 
neurons and microglia expressed ADAMTS4 that remained associated with the 
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cell surface, and that the ADAMTSs actively cleaved brevican in neurons and 
astrocytes.  A second series of experiments were conducted to elevate the level 
of ADAMTS4 in neuronal cultures which stimulated the extension of neurites from 
these neurons.  Increasing ADAMTS4 expression in dispersed, cultured neurons 
from embryonic rat forebrain increased the length of primary and secondary 
neurites, regardless of whether the enzyme was proteolytically active.  
ADAMTS4 treatment induced the appearance of phosphorylated ERK1/2 and the 
neurite promoting effect was entirely dependent upon activation of the ERK1/2 
MAPK pathway, as inhibitors of this pathway nearly completely diminished 
ADAMTS4-induced neurite outgrowth.  In the final study, treatment with 
ADAMTS4 induced alterations in dendritic spine morphology, including an 
increase in the proportion of immature dendritic filopodia that was associated 
with a concomitant decrease in post-synaptic PSD-95 immunoreactivity.  These 
results provide the original observation that ADAMTSs can influence neural 
plasticity and provide the foundation for further, more detailed investigation as to 
the mechanism of how the ADAMTS proteases affect neural plasticity. 
 At the initiation of these experiments, before directly testing the hypothesis 
that ADAMTSs could alter neural plasticity, it was of interest to characterize the 
expression patterns of brevican and ADAMTS4, and the proteolytic processing of 
brevican in these neural cultures because little to nothing was known about the 
deposition of brevican in neural cultures.  Conserved sequences near the N-
terminus of brevican, aggrecan and versican are the specific sites for ADAMTS 
cleavage in these proteins, with alternative MMP cleavage sites with conserved 
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sequences, located upstream in the proteins.  Using these known sequences, 
antibodies can be generated against the neoepitope peptide that is exposed 
upon cleavage by the ADAMTSs, and levels of cleaved substrate may be 
measured using these antibodies to provide an estimate of the activity of these 
proteases.  We used the anti-neoepitope antibody for rat brevican cleavage by 
the ADAMTSs, anti-EAVESE, in the experiments performed in published Paper 
1.  This antibody was useful in establishing that the ADAMTSs were active in 
cleaving brevican in our cultures (Fig. 3, middle panel) but more importantly, the 
measure of EAVESE as a proportion of the level of intact substrate could be 
used as an indirect measure of ADAMTS proteolytic activity (Fig. 6, lower 
panels). 
The above methods were utilized to determine the expression patterns of 
brevican and ADAMTS4 in neural cultures so that these cultures could eventually 
be used to test our hypothesis.  Brevican and its N-terminal cleavage fragment 
were detected in the medium of astrocytes and neurons, and several isoforms of 
intact brevican were found associated with the cell lysate fraction in these 
cultures (Fig. 3, upper panel).  No brevican expression was detected in the cell 
lysate or medium of microglial cultures (Fig. 3, upper panel).  The N-terminal 
cleavage fragment of brevican was detected in the medium of neurons and 
astrocytes, and not in the cell lysate (Fig. 3, upper and middle panels).  The N-
terminus of brevican contains a hyaluronan-binding domain and many studies 
exist to show that the lecticans bind to hyaluronan at the N-terminus and tenascin 
at the C-terminus to form a matrix lattice (Yamaguchi, 2000; Bruckner et al., 
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2003).  Since the N-terminal cleavage fragment of ADAMTS4 was detected in the 
medium and not cell lysate, it suggests that hyaluronan is not participating in any 
matrix formation in these cultures.  Brain link proteins (Bral) stabilize the 
interactions between hyaluronan and the lecticans (Oohashi et al., 2002; Bekku 
et al., 2003), and perhaps these proteins are not present or present in insufficient 
concentration to properly stabilize binding.  The expression patterns for link 
proteins in vitro are currently unknown. 
The presence of ADAMTS4-cleaved brevican indicated that these 
proteases were present and active in astrocytes and neurons, and ADAMTS4 
was detected in the cell lysate fraction of microglia, neurons and astrocytes (Fig. 
3, lower panel).  ADAMTS4 is produced with an N-terminal pro-domain that 
undergoes furin-mediated removal in the trans-Golgi network followed by 
secretion as a 68kD protein that is processed C-terminally to yield 53kD and 
40kD products (Flannery et al., 2002; Wang et al., 2004).  The 53kD form was 
detected in the cell lysate of astrocytes and neurons, and several forms were 
found in the cell lysate of microglia, all of which coordinated with the bands 
detected for human recombinant ADAMTS4 (Fig. 3, lower panel).  ADAMTSs are 
well established as proteases that bind pericellular region in many cell types in 
vitro, and accordingly, ADAMTS4 was not detected in the medium of any of the 
cultures examined (Kuno and Matsushima, 1998; Gao et al., 2004). 
We established that astrocytes produced a brevican-rich matrix, and we 
next attempted to modulate this matrix with cytokines and other factors.  Several 
studies show increased PG deposition including aggrecan, neurocan and 
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versican in response to TGFß in several cell and tissue types (Bassols and 
Massague, 1988; Asher et al., 2000; Stokes et al., 2001).  Other studies 
examining alterations in levels of ADAMTSs resulting from TGFβ treatment are 
not as clear and appear to be selective to the protease examined.  Others show 
that TGFβ decreased ADAMTS1 levels, while increasing ADAMTS4 levels, 
although the ADAMTS4 study also revealed increased TIMP activity in 
accordance with increased ADAMTS4 (Cross et al., 2005; Ng et al., 2006).  We 
found that TGFβ increased full-length brevican in the medium of astrocyte 
cultures through the inhibition of ADAMTS activity (Figs. 4, 7).  Our lab recently 
found that lipopolysaccharide (LPS) induced ADAMTS4 protein in vitro 
(unpublished findings), and LPS is known to stimulate the secretion of ADAMTS1 
(Kuno et al., 1997), indicating that ADAMTS4 may be a protease associated with 
inflammatory responses.  Since TGFβ is classically a cytokine that correlates 
with reduced inflammation, it is logical to find that TGFβ would reduce the activity 
of a protease potentiating the inflammatory response.   
 With characterization studies completed, the next series of experiments 
tested the hypothesis that increased cleavage of brevican by ADAMTSs results 
in altered neural plasticity.  The astrocyte culture, rich in a brevican ECM, was 
utilized as a growth substrate for neurons to more closely imitate the inhibitory in 
vitro conditions afforded by ECM PGs.  PGs are well-known inhibitors of neurite 
outgrowth, an effect that is dependent upon both the core protein and CS chains 
contained therein (Silver and Miller, 2004; Carulli et al., 2005).   
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Mounting evidence indicates that modifications of CS-containing PGs 
within the ECM can lead to physiologically relevant changes in the CNS.  The 
large number of studies of chondroitinase treatment indicate that removal of CS 
chains activate plasticity.  Modulation of CS-containing PGs activate plastic 
responses in the CNS, and chondroitinase treatment to remove the CS chains 
from PGs allowed for axonal penetration of a glial scar that was produced in 
response to injury (Moon et al., 2001).  Additionally, chondroitinase treatment 
resulted in reactivation of plasticity in visual cortex after the critical period in rats 
undergoing monocular deprivation (Pizzorusso et al., 2006).  The mechanism of 
inhibition by the core protein is still unclear, however, our lab and others have 
postulated that the interactions of CS-containing PGs of the lectican family with 
hyaluronan and tenascin, other ECM components, create a meshwork of ECM 
that is difficult for cells and neurites to penetrate, and that proteolytic degradation 
of the core protein may loosen these associations and afford increased plasticity 
(Yamaguchi, 2000); Fig.8, A, B).  There is evidence to demonstrate that 
proteolysis of the ECM is critical to activate the plastic response.  Increased 
protease expression occurs during regeneration, neuronal sprouting and 
synaptogenesis, and even more compelling, blocking proteolysis of the ECM 
impedes neural plasticity (Szklarczyk et al., 2002; Yuan et al., 2002; Reeves et 
al., 2003; Kim et al., 2005; Mayer et al., 2005).  We attempted to test the 
hypothesis that increased proteolysis of CS-containing PGs by ADAMTSs could 
alter synaptic plasticity.  To accomplish this, neurons were transfected with a 
vector to drive the expression of ADAMTS4, or empty vector as a control, and 
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applied to a monolayer of astrocytes to provide an inhibitory PG-rich matrix for 
which the neurons to extend neurites.  Initially, the experimental data supported 
this notion, and consistent with our hypothesis, neurons overexpressing 
ADAMTS4 extended longer neurites as compared to empty vector transfects 
(Fig. 9, E).  The increased length of neurites was initially attributed to escalated 
cleavage of PGs by ADAMTS4, however our next experiments suggested that 
proteolysis of ECM proteins by the ADAMTSs may not be important in the 
increases seen in neurite outgrowth.  To test this, we performed the experiment 
again but plated these transfected neurons on a permissive poly-l-lysine/laminin 
substrate where the increased expression of ADAMTS4 would not have 
abundant substrate produced by astrocytes to cleave, and interestingly, the same 
results were obtained (Fig. 10, E).  Neurons over-expressing ADAMTS4 
extended longer neurites, regardless of whether they were plated on an astrocyte 
monolayer secreting inhibitory CS-containing PGs or permissive poly-l-
lysine/laminin substrate (Figs. 9-10).  This was certainly surprising and indicated 
that the mechanism proposed in our hypothesis was not supported.  We next 
reformulated our hypothesis to presume that ADAMTS4 could exert biological 
effects in the absence of its proteolytic capacity.  Although there was no evidence 
to show that ADAMTSs could act in a non-proteolytic fashion, there were studies 
indicating that MMPs, a family of related proteases, could transduce cell signals 
in the absence of proteolytic activity.  For example, MMP-1 interacts with integrin 
receptors to stimulate dephosphorylation of Akt and induce apoptosis (Conant et 
al., 2004), and perhaps ADAMTSs could act in a similar fashion.  To more 
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directly test the notion that ADAMTS4 increases neurite length in the absence of 
proteolysis of CS-containing PGs, we repeated the previous experiment with an 
added parameter: a vector to drive the expression of proteolytically inactive, 
mutant ADAMTS4 protein (Gao et al., 2004), and plated these neurons on poly-l-
lysine/laminin substrate.  Surprisingly, mutant ADAMTS4 significantly increased 
neurite outgrowth in a manner similar to native human ADAMTS4-transfects (Fig. 
11, G), suggesting the possibility that ADAMTS4 was binding to a cell surface 
receptor to induce intracellular signals that resulted in longer neurite lengths.  
Interestingly, the thrombospondin motif and spacer region contained within 
ADAMTS family members mediate substrate binding (Kuno and Matsushima, 
1998; Kashiwagi et al., 2004), and perhaps this interaction may be the means 
through which ADAMTS4 is binding to an unknown cell surface receptor to 
activate signaling. 
Given the domains of ADAMTS4 and the binding patterns of proteins with 
similar domains, there are many cell surface receptors that ADAMTS4 could bind 
to transduce cell signals to stimulate neurite outgrowth.  ADAMTS4 contains TSP 
motifs, and TSP itself induces neurite outgrowth through the activation of 
integrins (Neugebauer et al., 1991; DeFreitas et al., 1995), which are well-known 
cell surface signal transducers.  Interestingly, this effect could be blocked by 
heparin, indicating that the binding may be mediated by a PG containing heparan 
sulfate or a sulfated glycolipid (Neugebauer et al., 1991).  Clearly TSP increases 
neurite outgrowth, but can a TSP motif act in a similar way?  Studies with the 
protein SCO-spondin, with 26 TSP repeats, indicate that this is the case.  This 
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protein increases neurite outgrowth in a variety of neurons and neuron-like cells, 
and this action is mediated by the interaction of a sequence in the TSP motif, 
WSGWSSCSRSCG, with α1β1 integrin (Monnerie et al., 1998; Gobron et al., 
2000; El-Bitar et al., 2001; Bamdad et al., 2004).  Thus, perhaps the TSP motifs 
of ADAMTS4 could act similarly to activate integrin signaling to increase neurite 
outgrowth.  We attempted preliminary experiments with integrin antibodies to 
block integrin ligands and signal transduction to determine if this could attenuate 
ADAMTS4-mediated increases in neurite outgrowth, and encountered difficulties 
when basal neurite outgrowth was inhibited (data not shown).  Thus, it may be 
difficult with this type of experiment to determine which integrins, if any, play a 
role in signaling via the ADAMTSs to increase neurite outgrowth if these integrins 
are essential for normal neurite outgrowth. 
Interactions of ADAMTS4 with other moieties may be the means through 
which this protease is stimulating cell signaling.  The ADAMTSs bind ECM 
components like heparan sulfate (HS) and CS, and in fact, this association is 
important for substrate binding and cleavage (Tortorella et al., 2000; Flannery et 
al., 2002; Kashiwagi et al., 2004).  ADAMTS4 binds the HS of syndecan-1, but it 
is unknown whether this binding is necessary to induce cell signals (Gao et al., 
2004).  Neurocan, typically inhibitory to neurite outgrowth, when bound to 
HSPGs, promotes neurite outgrowth, although it is unknown whether this 
interaction is a sequestering phenomena or whether signals are induced through 
the interaction between neurocan and HSPGs (Akita et al., 2004).  Heparin-
binding growth associated molecule (HB-GAM) binds syndecan-3 to increase 
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neurite outgrowth, an association that is mediated by the heparan sulfate chains 
of syndecan-3 (Raulo et al., 1994; Kinnunen et al., 1996).  Furthermore, 
syndecans play important roles during development to promote neuronal cell 
migration (Toba et al., 2002).  Thus, it is plausible that ADAMTS4 could be 
interacting with syndecan HS to promote neurite outgrowth. 
We next attempted to elucidate the cell signals induced by ADAMTS4 to 
examine whether the intracellular signaling pathways known to be involved in 
ligand-induced neurite plasticity were also stimulated by the action of the 
ADAMTSs.  Human recombinant ADAMTS4 was added to the culture medium of 
neurons growing on poly-l-lysine/laminin substrate, and the cell lysate collected 
at 20, 40 and 60 minutes after addition to determine the levels of various signals 
that were induced by ADAMTS4 treatment (Figs. 13, 14).  Analysis of alterations 
in general protein phosphotyrosine levels revealed changes in several proteins 
(Fig. 13, A-F), and analyses with antibodies specific to phospho-ERK1/2 revealed 
that there were increases in activated, phospho-ERK1/2 MAPK in neuronal 
cultures treated with human recombinant ADAMTS4 compared to vehicle-treated 
controls (Fig. 14, A-D).  It is important to note, however, that the human 
recombinant enzyme preparations utilized in these studies were purified at 
Roche Biosciences, and while these proteases are presumed to be pure, the 
exact protein character of the prerarations is unknown, and the possibility that the 
effects detected in response to ADAMTS treatment are due to a contaminating 
substance cannot yet be eliminated.  Further studies are necessary to fully 
investigate this possibility.  More importantly, blockade of the MAPK pathway 
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attenuated the ADAMTS-mediated increases in neurite outgrowth (Fig. 15, A-C), 
suggesting a vital role for the ERK MAPK pathway in ADAMTS-induced neurite 
outgrowth.   
Activation of the MAPK pathway is important in inducing neurite outgrowth 
in a variety of neuronal-like cell types such as neuroblastoma cells, NG108-15 
cells and hippocampal neurons (Schmid et al., 2000; Gerecke et al., 2004; Gu et 
al., 2005), but can interactions with syndecans or integrins, (as proposed cell 
surface receptors for ADAMTS4) stimulate the MAPK pathway to modulate 
neurite outgrowth?  The α1 integrin subunit binds protein tyrosine phosphatase 
(PRL-3) to activate ERK1/2 and increase neurite outgrowth (Peng et al., 2006).  
Additionally, connective tissue growth factor (CCN-2), which like ADAMTS4, 
possesses a thrombospondin type-1 motif, binds syndecan-2 to activate ERK1/2 
signaling (Chen et al., 2004), so ADAMTS4 could interact with syndecans or 
integrins to stimulate ERK1/2 signaling.  Furthermore, interactions of ADAMTS4 
with PGs may even mediate this effect.  Basic fibroblast growth factor (FGF)-2 
binds HS on the PG agrin to activate ERK1/2 signaling and alter neurite 
outgrowth in PC-12 cells (Kim et al., 2003), although this may be an HS selective 
event.  ADAMTS4 could orient FGF-2 binding to HS on agrin, however, agrin 
expression is low in the CNS relative to the PNS, so this may be unlikely or could 
occur via another PG that contains HS in the CNS.  The cell surface receptor 
activated by binding ADAMTS4 is currently unknown, and at this point, our 
research only allows for speculation, so further studies are needed to determine 
the identity of this receptor.   
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 Since ADAMTS4 increases neurite outgrowth, it clearly was of interest as 
to whether the ADAMTSs may influence other parameters of morphological 
neural plasticity, such as synapse-associated plasticity.  It is largely unknown 
what role ECM proteases play in synaptogenesis and synaptic reorganization, 
although indirect evidence indicates that these proteases may be important in 
this capacity since ADAMTSs are increased during periods of synaptic 
restructuring in the adult nervous system (Yuan et al., 2002; Mayer et al., 2005).  
Alterations in the morphology of dendritic spines are correlated with functional 
and structural changes at the post-synaptic density and more generally, can 
influence behavior (Engert and Bonhoeffer, 1999).  Thus, to analyze alterations 
in dendritic spine morphology in response to ADAMTS4, neuronal cultures were 
treated with 50nM human recombinant ADAMTS4 for 2-3 days, the neurons were 
fixed with 4% paraformaldehyde and immunostained for actin, a protein whose 
polymerized filaments are abundant and concentrated in dendritic spines.  
Dendritic spines were visualized by confocal microscopy, counted in segments of 
10µm, and protrusion length and the diameters of the neck and head of the 
protrusion were measured.  Significant increases in the overall lengths of 
dendritic protrusions were detected in response to ADAMTS4 treatment (Fig. 16, 
D).  Increased protrusion length is an indication of immaturity, and to further 
investigate the possibility that ADAMTS4 was inhibiting the maturation of 
dendritic spines, specific morphological types of spines were examined.  
Dendritic spines may begin as filopodia that are seeking a synaptic contact, and 
these may disappear or mature into a dendritic spine, which may be subdivided 
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into several morphological types: thin, mushroom and stubby, with thin being the 
most immature of the three, and stubby being the most mature and stable (Ziv 
and Smith, 1996; Fiala et al., 1998; Harris, 1999).  ADAMTS4 treatment resulted 
in increased percentage of filopodia, in both young and mature cultures (Fig. 17), 
indicating that ADAMTS4 may be important in preventing the maturation of 
synapses or in inducing the formation of new filopodia.  This increase in filopodia 
was accompanied by decreases in PSD-95 immunoreactivity in the post-synaptic 
density of neurites of neurons transfected with native or mutant ADAMTS4 (Fig. 
22, E).  Since these neurons were grown on permissive poly-l-lysine/laminin 
substrate and since the mutant ADAMTS4 construct yielded similar results, it is 
likely that the effects seen on synaptogenesis with ADAMTS4 treatment is 
independent of proteolysis, however, further studies are needed to determine 
whether this is the case or not.  Regardless of how ADAMTS4 is acting to alter 
synaptic maturation, the results presented in paper 3 implicate ADAMTS4 as an 
important mediator of synaptic morphology and therefore, function.  These 
actions of ADAMTS4 may have wide-range consequences, for instance, if 
mature spines can be destabilized and reversed to an immature phenotype, this 
could lead to new synaptic connections or perhaps a loss of current synapses.  
Additionally, this effect could provide a mechanism for the loss of synapses that 
occurs in many inflammatory conditions where ADAMTS expression is increased.  
At any rate, the effect of ADAMTS4 in altering synaptogenesis is clearly novel 
and potentially significant.  Further studies are required to determine how 
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ADAMTS4 is acting in the exquisite regulation of synapse formation and 
maintenance.   
 As with increases in neurite outgrowth, it is possible that the effects of 
ADAMTS4 on synapse morphology and function are mediated by the integrins.  
Integrins mediate effects on synaptic maturation, LTP, and NMDA receptor 
responses (Chavis and Westbrook, 2001; Chan et al., 2003; Lin et al., 2003; 
Bernard-Trifilo et al., 2005).  Even more interesting, hippocampal neurons treated 
with an RGD-containing peptide to activate integrins exhibit increased spine 
length and increased numbers of filopodia, similar to the results of the studies in 
Paper 3 (Shi and Ethell, 2006).  Alternatively, a syndecan family member could 
play a role in mediating this effect, since syndecan-2 has been shown to be a key 
regulator of dendritic spine formation.  Induction of syndecan-2 expression in 
immature hippocampal neurons resulted in clustering of syndecan-2 and the 
formation of mature dendritic spines (Ethell and Yamaguchi, 1999).  This effect 
was regulated by EphB2 receptor tyrosine kinase, which phosphorylates 
syndecan-2 (Ethell et al., 2001).  Again, since ADAMTS4 may be able to bind 
and/or activate integrin receptors or syndecan HSPGs, these associations may 
play a role in dendritic spine formation. 
 This manuscript provides evidence that ADAMTS4 increases neurite 
lengths and prevents maturation of dendritic spines, however, it is currently 
unknown how the secretion of ADAMTSs in vivo affects neural plasticity, and 
whether or not ADAMTSs are critical for neurite outgrowth and synaptogenesis.  
ADAMTS4 is secreted by astrocytes, neurons and microglia, and these cells 
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could potentially alter neural plasticity through the production of ADAMTS4 or 
other ADAMTSs (Fig. 23).  While it is clear that ADAMTS4 is secreted and binds 
the cell surface, the cellular origin of such ADAMTS4 protein is unknown, and 
could potentially be secreted from neurons at the dendrite and/or axon to alter 
neurite outgrowth (A).  Furthermore, since astrocytes and microglia express 
ADAMTS4, the role of these cells in ADAMTS-mediated neurite outgrowth is 
possible and cannot be ignored (B, C).  In addition to neurite outgrowth, dendritic 
spine maturation could be altered by secretion of ADAMTS4 from neurons (D), 
astrocytes (G) or microglia (H).  Furthermore, ADAMTSs may exert effects on 
other CNS processes like astrocyte reactivity and microglial migration and 
invasion where a remodeling of the CNS is necessary for these processes to 
occur (E, F).  Although we provide evidence to indicate that the ADAMTSs 
mediate neural plasticity in a non-proteolytic manner, there may be a balance 
between the proteolytic and non-proteolytic actions of ADAMTS4 in regulating 
neural plastic processes.   
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Figure. 23: ADAMTS4 mediates neural plasticity.  Neurons, astrocytes and 
microglia secrete ADAMTS4 and potentially mediate neurite outgrowth and 
synaptogenesis in vivo (A-D, G, H).  Furthermore, secretion of ADAMTS4 by 
astrocytes and microglia may play a role in astrocyte reactivity (E) and microglial 
migration and invasion (F). 
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In sum, the studies presented here provide evidence that ADAMTS4 can 
modulate neural plasticity in a non-proteolytic-dependent manner.  These are the 
very first studies to indicate that ADAMTSs can act in a capacity other than a 
protease, and even more exciting, that they modulate neurite outgrowth and 
synaptogenesis.  Further studies are needed to elucidate the exact function of 
ADAMTS4 in these processes, and there is still much work to be done to identify 
the cell surface receptor and the entire signal cascade that remains obscured 
between ADAMTS4 addition and alterations detected in neurite outgrowth and 
synaptogenesis.  Once elucidated, perhaps the ADAMTSs can be utilized as 
therapeutic targets in patients with traumatic brain or spinal cord injury where the 
formation of a glial scar in response to the injury results in an inhibitory 
environment that hampers plasticity and complete recovery of the CNS.  This 
resistance to plasticity in the adult brain perhaps could be altered with ADAMTS4 
treatment.  Of course, there is a great deal of work to be done to understand the 
exquisite regulation between protecting established synapses and forming new 
ones.  In a brain that is injured, the outgrowth of neurites and filopodia could 
provide a means for new synaptic contacts and recapture of function, but of 
course, it is paramount to regulate this process to prevent the formation of 
aberrant connections.  Furthermore, if ADAMTS4 induces the reversal of mature 
contacts, this could result in the loss of function and memories, and be very 
destructive, so it will be extremely exciting to research this area further to 
determine the exact roles for the ADAMTSs in neural plasticity and in treatment 
of the damaged CNS.  Overall, these studies provide compelling evidence that 
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ADAMTS4 acts in a non-proteolytic manner to increase neurite outgrowth and 
prevent synapse maturation in vitro.  These are the first experiments to implicate 
the importance of ADAMTS4 in neural plasticity, and even more surprising, that 
these effects are mediated by cell signaling rather than proteolysis. 
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